



Signed 11-APR-2026

Basem M. William, MD, MRCP (UK), FACP

500 Thomas Lane A3. Columbus, OH 43214

Phone 614-566-2500 - Fax 614-533-0335- Cell 402-661-9504

basem.william@ohiohealth.com

Last updated: March 28, 2026

<https://www.linkedin.com/in/basem-m-william-md-mrcp-uk-facp-936633104/>

Brief Biography

Dr Basem William is a hematologist with an internationally recognized expertise in hematological malignancies, lymphoma, T-cell lymphomas, Cutaneous Lymphomas, drug development, hematopoietic stem cell transplantation and cellular therapy. He has been a PI/co-investigator/site PI on over 100 clinical trials in hematological malignancies and cell therapy. He published over 80 peer reviewed articles, over 120 peer-reviewed abstracts, and 5 book chapters and has previously served on the NCCN Guidelines expert panel in T-cell Lymphomas. He is certified by the American Board of Internal Medicine in Hematology, Oncology, Internal Medicine, and Hospice/Palliative Medicine and is a member of the Royal Colleges of Physicians of the United Kingdom. After leading the T-cell lymphoma program at the Ohio State University Comprehensive Cancer Center, where he was an Associate Professor of Internal Medicine, for 4 years, he recently joined OhioHealth Health system to help build a new comprehensive hematological malignancies, transplant, and cell therapy program. He has been a FACT inspector since 2018 and a member of FACT immune effector cell (IEC) taskforce and Education, and IEC standards Committees. He was appointed the institutional PI for the Alliance of Clinical Trials in Oncology at Riverside Methodist Hospital since October 2022. Recently, he was appointed as the **John P. McConnell Endowed Chair for Cancer Research, by the OhioHealth Foundation, to build a new Oncology Phase I Clinical Trials Program.**

Current Position(s)

Staff Physician, Hematology/Oncology OhioHealth Physician Group	3/2021-present
--	----------------

Clinical Director, Blood and Marrow Transplant Program Medical Director, Cell Therapy Laboratory Medical Director, Immune Effector Cell Program Facility Director, Marrow Collection Facility OhioHealth Riverside Methodist Hospital/Bing Cancer Center Columbus, OH	3/2021-present
--	----------------

Institutional Principal Investigator, Alliance of Clinical Trials in Oncology OhioHealth Riverside Methodist Hospital Columbus, OH	10/2022-present
--	-----------------

John P. McConnell Endowed Chair for Cancer Research OhioHealth Foundation Columbus, OH	11/2023-present
---	------------------------

Education *[Note: in reverse chronological order]*

Clinical Fellow, Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE.	09/2009-06/2012
--	-----------------

Membership of the Royal College of Physicians of the United Kingdom (MRCP) Diploma, London, UK	4/2005
---	--------

House-Staff (Intern and Resident) Internal Medicine, University of Pittsburgh Medical Center (UPMC) McKeesport, Pittsburgh, PA	7/2002 – 7/2005
--	-----------------

Masters of Internal Medicine degree (M.Sc.), Faculty of Medicine, Ain Shams University, Cairo, Egypt	5/2001
Bachelor of Medicine and Surgery degree (M.B.B.Ch), Faculty of Medicine, Ain Shams University, Cairo, Egypt	12/1996

Academic Appointments

Professor (Adjunct) Department of Biomedical Education and Anatomy The Ohio State University – College of Medicine Columbus, OH	6/2024-pres
Associate Professor (Adjunct) Department of Biomedical Education and Anatomy The Ohio State University – College of Medicine Columbus, OH	6/2023-2/2024
Associate Professor Division of Hematology, Department of Internal Medicine Lymphoma and Blood & Marrow Transplant programs The Ohio State University – College of Medicine Columbus, OH	6/2019-2/2021
Assistant Professor Division of Hematology, Department of Internal Medicine Lymphoma and Blood & Marrow Transplant programs The Ohio State University – College of Medicine Columbus, OH	9/2015-5/2019
Assistant Professor Division of Hematology/Oncology, Hematological Malignancies/Stem Cell Transplant Program, Department of Medicine, University Hospitals Case Western Reserve Cleveland, OH	8/2012-7/2015
Instructor, Department of Medicine, Clinical Hematology and Oncology unit, Faculty of Medicine, Ain Shams University and Hospitals, Cairo, Egypt	9/2001– 6/2002

Professional Positions and Experience

Postdoctoral, Leukemia Research/preclinical drug Development The Jackson Laboratory, Bar Harbor, ME	10/2005 - 11/2017
Director, Radiation Injury Treatment Network (RITN), University Hospitals Case Medical Center, Cleveland, OH	7/2013 – 7/2015
Staff Physician (Hospitalist) Alegent Health Midlands Hospital Papillion, NE.	12/2008 – 6/2009
Special Fellow, Myeloproliferative diseases Hematology/Oncology,	7/2008 – 8/2008

Weill Cornell Medical Center
New York, NY

Staff Physician (Hospitalist)
Washington Hospital Center,
Washington, DC.

1/2008 – 6/2008

Staff Physician (Hospitalist/Palliative Medicine)
Eastern Maine Medical Center,
Bangor, ME.

8/2005 – 12/2007

Staff physician and Associate Director
Medical ICU and Apheresis services,
Ain Shams University Hospitals,
Cairo, Egypt

6/2001 –6/2002

House-Staff, Internal Medicine/Clinical Hematology and Oncology
at the Ain Shams University Hospitals,
(including training in Nephrology/Medicine
Elmhurst Hospital Center,
Elmhurst, NY)
Cairo, Egypt

5/1998 –5/2001

General practitioner
El-Salam health administration,
Egyptian Ministry of Health
Cairo, Egypt

4/1998 – 5/1998

Pre-registration house-officer (rotating internship)
Ain Shams University Hospitals and
El-Sahel Teaching Hospital
(including a clinical rotation in
Hematology at the Johns Hopkins Hospital, Baltimore, MD)
Cairo, Egypt

3/1997 – 2/1998

Professional/Educational Leadership Experience

Director, T-cell Lymphoma Program
Program Director, Cutaneous Lymphoma Research Fellowship

9/2016-11/2020
9/2016-6/2020

Certification and Licensure

Years

American Board of Internal Medicine (ABIM)
Re-certified in Internal Medicine
American Board of Internal Medicine (ABIM)
Re-certified in Hematology
American Board of Internal Medicine (ABIM)
Re-certified in Medical Oncology
American Board of Internal Medicine (ABIM)
Re-certified in Hospice and Palliative Medicine
American Board of Internal Medicine (ABIM)
Re-certified in Internal Medicine
American Board of Internal Medicine (ABIM)
Certified in Hematology
American Board of Internal Medicine (ABIM)

11/2025
11/2021
11/2021
11/2017
08/2015
10/2012
10/2012

Certified in Medical Oncology	
Medical License, State of Ohio	05/2012
American Board of Internal Medicine (ABIM)	
Certified in Hospice and Palliative Medicine	10/2008
American Board of Internal Medicine (ABIM) Certified in Internal Medicine	08/2005
Educational Commission of Foreign Medical Graduates (ECFMG)	07/1998
Certification Philadelphia, PA (permanently valid)	

Professional Development *[Note: List in reverse chronological order, include year]*

Professional Memberships and Activities

Member, International Society of Cutaneous Lymphomas	2018-2020
	2026-Pres
Member, ASCO International Development and Education Award (IDEA) Steering Group	2026-pres
Panelist, American Board Certified Doctors for Egypt (ABCDE) hematology tumor board	2/2026
Expert Reviewer, UK government's Metascience/Unv of Sussex Unit Novelty Indicators	2026
Primum Health, Lymphoma Expert Panel	2026-Pres
Facilitator, FACT New Inspector Training Course	2/2026
Member, CAR-T vision working group	2025-pres
Member, United State Cutaneous Lymphoma Consortium	2018-2020
	2025-Pres
Facilitator, FACT New Inspector Training Course	2/2025
Speaker, FACT accreditation workshop pre-tandem	2/2025
Faculty, ASH Annual Meeting Career Development Lunch	12/2024
ISCT Hands-on Laboratory Bootcamp for Cell Therapy Biomanufacturing, Georgia Tech University	8/2024
Member, International Society of Cell Therapy (ISCT)	7/2024
Facilitator, FACT New Inspector Training Course	2/2024
Invited panelist, Deloitte NextGen Therapy Industry Working Group	3/14/2023
Author, American Board of Internal Medicine Hematology Item Writer Task Force	2022-Pres
Physician Advocate, MD Anderson Physicians Network	2022-2023
Invited panelist, Lymphoma session, Bioascend Beyond the Congress: Key Conversations from the 2021 Hematology Annual Meeting	2022
Author, Question Writing Group, ASCO Self Assessment Program (SAP)	2021-2022
Member, Alliance of Clinical Trials in Oncology (formerly CALGB) Lymphoma and Transplant and Cellular Therapies Committees	2020-Pres
Judge, ACP Ohio Western Chapter Resident Abstract Competition, American College of Physician (ACP) Ohio Chapter Meeting	2019-Pres
Author, ASH News Daily 2019. The American Society of Hematology Annual Meeting Newspaper	2019
Mednet, Lymphoma Expert Panel	2018-Pres
Member, Society of Investigative Dermatology	2018-2019
Member, National Comprehensive Cancer Network (NCCN) Expert Panel Member for T-cell Lymphoma and Cutaneous B-cell Lymphoma NCCN Guidelines	2017-2020
Fellow of the American College of Physicians (FACP)	2015-Pres
Member of the Center of International Blood and Marrow Transplantation Research (CIBMTR); lymphoma, myeloma, chronic leukemia, late effects and quality of life, and immunobiology working committees	2013-Pres
Member of the American Society of Hematology (ASH)	2012-Pres
Member of the American Society of Clinical Oncology (ASCO)	2012-Pres
Member of the American Society of Transplant and Cellular Therapy (ASTCT)	2012-Pres
Member of the American College of Physicians (ACP)	2005-Pres
Member of the Royal College of Physicians of London (MRCP London)	2005-2015
Member of the Egyptian Medical Syndicate	1998-Pres

Editorial Board Appointments

[List in reverse chronological order]

Include relevant dates

Associate Editor: Discover Oncology	2026-Pres
Ad Hoc Reviewer: Technology in Cancer Research & Treatment	2026-Pres
Ad Hoc Reviewer: MedComm	2026-Pres
Ad Hoc Reviewer: Viruses	2026-Pres
Ad Hoc Reviewer: Journal of Immunotherapy of Cancer	2025-Pres
Ad Hoc Reviewer: Stem Cells	2025-Pres
Ad Hoc Reviewer: British Journal of Dermatology	2025-Pres
Associate Editor: Therapeutic advances in Hematology	2025-Pres
Ad Hoc Reviewer: Frontiers in Immunology	2025-Pres
Ad Hoc Reviewer: Clinical Kidney International	2025-Pres
Ad Hoc Reviewer: Hematological Oncology	2025-Pres
Ad Hoc Reviewer: AME Clinical Trial Review	2025-Pres
Ad Hoc Reviewer: European Journal of Hematology	2025-Pres
Ad Hoc Reviewer: Cancer Communications	2025-Pres
Ad Hoc Reviewer: Discover Oncology	2025-Pres
Ad Hoc Reviewer: Drug Design, Development and Therapy	2025-Pres
Ad Hoc Reviewer: Blood and Lymphatic Cancer: Targets and Therapy	2024-Pres
Ad Hoc Reviewer: Cancer Management and Research	2024-Pres
Ad Hoc Reviewer: Targeted Oncology	2024-Pres
Ad Hoc Reviewer: British Medical Journal (BMJ)	2022-Pres
Ad Hoc Reviewer: Journal of Translational Medicine	2022-Pres
Ad Hoc Reviewer: Therapeutic advances in Hematology	2020-Pres
Ad Hoc Reviewer: Journal of Investigative Dermatology	2020-Pres
Ad Hoc Reviewer: Blood Advances	2020-Pres
Ad Hoc Reviewer: Clinical Lymphoma Myeloma and Leukemia	2020-Pres
Ad Hoc Reviewer: Journal of International Medical Research	2020-Pres
Ad Hoc Reviewer: Cancer	2019-Pres
Ad Hoc Reviewer: Lancet Hematology	2019-Pres
Ad Hoc Reviewer: British Journal of Haematology	2019-Pres
Frontiers in Oncology, editor, special issue on Cutaneous T-cell Lymphomas	2018-Pres
Frontiers in Oncology, associate editor section of Hematological Malignancies	2018-2021
Ad Hoc Reviewer: European Medical Journal	2018-Pres
Ad Hoc Reviewer: Chinese Clinical Oncology	2018-Pres
Ad Hoc Reviewer: Blood	2017-Pres
Ad Hoc Reviewer: Biology of Blood and Marrow Transplantation	2017-Pres
Ad Hoc Reviewer: Leukemia and Lymphoma	2017-Pres
Ad Hoc Reviewer: Clinical Transplantation	2017-Pres
Ad Hoc Reviewer: American College of Physician MK-SAP 18	2016-Pres
Ad Hoc Reviewer: PLOS One	2016-Pres
Ad Hoc Reviewer: Springer Plus	2016-Pres
Ad Hoc Reviewer: Frontiers in Oncology	2016-Pres
Ad Hoc Reviewer: Journal of International Medical Research	2016-Pres
Ad Hoc Reviewer: Drugs	2016-Pres
Ad Hoc Reviewer: BMC Cancer	2015-Pres
Ad Hoc Reviewer: Acta Hematologica	2015-Pres
Ad Hoc Reviewer: Rejuvenation Research	2015-Pres
Ad Hoc Reviewer: Bone Marrow Transplantation	2014-Pres
Ad Hoc Reviewer: Brazilian Journal of Hematology and Hematotherapy	2014-Pres
Ad Hoc Reviewer: Journal of Infection	2007-Pres
Ad Hoc Reviewer: European Journal of Gastroenterology and Hepatology	2007-Pres

Committee Assignments and Administrative Services

[List in reverse chronological order, noting leadership positions held. Include university and non-university activities (e.g., work with NIH study groups).]

Chair, OhioHealth Cancer Service Line Scientific Research Steering Committee	4/2025-Pres
Speaker, ASH-a-Palooza (ASH Friday Trainee Day)	12/2025
Session Chair/Moderator, ASH Annual Meeting	12/2024
Abstract Reviewer, ASH Annual Meeting	8/2024
Member, FACT Standards committee	2023-Pres
Member, FACT Education Committee	2023-Pres
Preceptor, OSU Longitudinal Practice Program, OSU College of Medicine	2022-Pres
Member, FACT Immune Effector Cell (IEC) Task Force	2020-Pres
Inspector, Federation for Accreditation of Cellular Therapy (FACT)	2018-Pres
Member, The Ohio State University Cancer Institutional Review Board (IRB)	9/2018-11/2020
Clinical Operations Taskforce, Division of Hematology, Department of Internal Medicine	1/2018-11/2020
Antibiotic Sub-Committee, Pharmacy and Therapeutics/Medication Use	11/2016-2/2017
Evaluation Committee, OSU Wexner Medical Center	

Clinical / Quality Improvement Activities

(List clinical responsibilities and other clinical activities that include number of weeks, and percentage/time effort)

BMT patient-donor evaluation process improvement taskforce, OSU James Cancer, OSU Wexner Medical Center Center	1/2017-1/2018
--	---------------

Educational Activities

MENTORSHIP

Undergraduate Students

<u>Merielle William</u> , Dublin Jerome High School Project(s): Curcumin and resveratrol sensitizes TP53 mutant acute myeloid leukemia (AML) cell lines to venetoclax-induced apoptosis	2025-Pres
<u>Anthony Bartholomew</u> , Ohio State University, College of Arts and Sciences Project(s): developing an automated platform for mSWAT analysis for CTCL Co-mentoring with Matt Lewis, PhD (OSU College of Arts Sciences)	2019 – 2020

Graduate Students

<u>Shihyoung Kim</u> , Ohio State University College of Veterinary Medicine Veterinary Biosciences Project(s): CD3e-immunotoxin-based lymphodepletion to enhance adoptive T cell transfer for HIV/AIDS therapy My role: Graduate Committee Member	2020-2021
--	-----------

Medical Students

<u>Britney Le (DO Candidate)</u> , Ohio University Heritage Collage of Osteopathic Medicine Project(s): Racial disparities in patients with Cutaneous Lymphomas My role: Research Mentor	2024-Pres
<u>Mia Loposser and Nazif Vardar (MD Candidates)</u> , Ohio State College of Medicine	2024-Pres

Clinic Mentor, OSU Longitudinal Practice Program

Vikrant Reddy and William Pelligrino (MD Candidates). Ohio State College of Medicine
Clinic Mentor, OSU Longitudinal Practice Program 2022-2024

David Clever (MD/PhD Candidate). Ohio State College of Medicine 2018-2019
Project: Regulatory T-cells in Cutaneous T-cell lymphomas.
Co-mentor with Anjali Mishra, PhD.

Adam G. Starr. Case Western University School of Medicine. 2014–2015
Project(s): Retrospective analysis of marginal cell lymphomas; a dual institutional experience (Case Medical Center and Cleveland Clinic).
Presented a poster at ASCO and published 3 manuscripts.

Mira Massoud. Case Western University School of Medicine. 2014 – 2015
Project(s):
1. Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience (*Published in Rev Bras Hematol Hemoter. 2016*)
2. Dual institutional experience of marginal zone lymphoma (*co-author on 3 manuscripts with Adam Starr*)

Internal Medicine Residents

Ysaith Orellana Ascencio. ASH HIP Resident Mentor Matching Program 2026 – pres
UT Health Houston, Houston, TX
Project(s):
Morbidity and Mortality of Patients with Acute COVID-19 Infection and Active Malignancy
– *Protocol in preparation*

Noha Sorrow. Western Reserve Health Education, Warren, OH 2020 – 2024
Project(s):
Impact of Opioid Use after Blood and Marrow Transplantation (BMT)
Poster presented at ASH 2020 and ASTCT 2021 meeting
– *manuscript in preparation*

Racial disparities in mycosis fungoides (SEER Database analysis)
*Poster presented at ASH 2021 – **recipient of ASH Abstract Achievement Award***

Michael Ozga. The Ohio State University College of Medicine. 2019 – 2020
Project(s):
Predictors of relapse after haploidentical hematopoietic stem cell transplantation
Poster presented at TCT 2020 meeting – manuscript in preparation

Andrew Schaefer. The Ohio State University College of Medicine. 2018 – 2019
Project(s):
Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion;
Patterns and Outcomes
Poster presented at TCT 2019 meeting – manuscript under peer review

Caner Saygin. The Ohio State University College of Medicine. 2017 – 2018
Project(s):
Incidence Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation
ASH 2018 poster

Nathan Denlinger. The Ohio State University College of Medicine. 2016 – 2019

Project (s):

- 85. Impact of Pre-Treatment Lymphopenia in patients with T-Cell Lymphomas
(*ASCO abstract Manuscript being reviewed by ao-authors*)
- 85. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib (*Review article –published in Cancer Management and Research 2018*)
- 85. Outcomes of Patients with Newly Diagnosed Peripheral T-cell Lymphoma Treated with Aggressive Chemotherapy, including Cutaneous Gamma-Delta T cell Lymphoma
(*Collaboration with Cleveland Clinic and Rutgers – poster presented ASH 2019*)

Patrick Eulitt. The Ohio State University College of Medicine. 2015 – 2016

Project: Waldenström's macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125 (*Case Report; published*)

Bryan Hambley. Case Western University School of Medicine. 2014 – 2015

Project: Bortezomib for the treatment of mantle cell lymphoma: an update
(*Review; published in Ther Adv Hematol. 2016*)

Hematology/Oncology Fellows

Sara Singer. The Ohio State University College of Medicine. 2018 – 2020

Project: A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplant
Trial open to accrual.
Review article published

Walter Hanel. The Ohio State University College of Medicine. 2018 – 2021

Projects:

- 77. A phase I study evaluating the safety and efficacy of <CONFIDENTIAL> in relapsed refractory PTCL and CTCL (*trial abandoned by sponsor*)
- 78. A phase I study of romidepsin in combination with piasclisib in relapsed and refractory T-cell lymphomas
Study is IRB approved and awaiting activation

Joseph Maakaron. The Ohio State University College of Medicine. 2017 – 2019

Project: A phase I, open-label, dose-escalation study of Venetoclax and BEAM conditioning followed by autologous stem cell transplantation for patients with relapsed, refractory, or high-risk non-Hodgkin lymphoma
Clinical trial fully accrued, presented at ASH and IMCL Lugano 2019
Update presented at 2021 TCT meeting
Manuscript in preparation

Masumi Ueda. Case Western University School of Medicine. 2014 – 2015

Project: DNMT1 as pharmacodynamics endpoint of hypomethylating agent therapy in AML
Presented at ASH 2017 and manuscript published

Cutaneous Lymphoma Research Fellows

Amy Johnson. The Ohio State University College of Medicine. 2019-2020

Project(s):

- 1. Paradoxical response of cutaneous T-cell lymphoma in a patient with concomitant angioimmunoblastic Tcell lymphoma (Case Report)
 - 2. Robust graft-versus-host response mimicking peripheral T-cell lymphoma relapse (Case Report)
- Two oral presentations at the World Conference on Cutaneous Lymphoma in 2020*

Aleeza Abbasi. The Ohio State University College of Medicine. 2018 – 2019
Project(s):

- 74. Identification and quantitation of tumor-specific T-cell clonotypes in tumor tissue and blood of patients with cutaneous T-cell lymphoma (CTCL): a retrospective study (*Project abandoned as collaborator moved out of institution*)
- 74. Case Series: The Treatment of Hypereosinophilic Disorder- Lymphocytic Variant with Romidepsin (*Manuscript published at CLML*)

Jessica Collins. The Ohio State University College of Medicine. 2017 – 2018
Project(s): Primary Cutaneous Pleomorphic Small-Medium CD4+ T-Cell Lymphoma: A Case Series *Presented in international T-cell forum 2018*

Sook Hwang. The Ohio State University College of Medicine. 2016 – 2017
Project (s): Imiquimod 5% topical monotherapy for indolent primary cutaneous B-cell lymphomas: a single-institution experience
Manuscript published at British Journal of Dermatology

Other advanced fellows

Samuel Yang. The Ohio State University College of Medicine. 2019 – 2020
Current position: Clinical Informatics Fellow PGY-5 (OSU)
Project(s): Developing a mobile device app to monitor patients with Cutaneous Lymphoma quality of life
Protocol is IRB approved; study awaiting activation

Alamdar Jafarov. OhioHealth Bing Cancer Center 6/2023
Current Position: Hematologist, Azerbaijan Medical University
Project(s): ASCO International and Education Award (IDEA) recipient

Mohammed Baker. ASCO Virtual Mentoring Program 3/2023-3/2024
Current Position: Housestaff, Faculty of Medicine,
Jordan University of Science and Technology, Jordan
Project(s): Racial disparities in Cutaneous Lymphoma

Pharmacy Residents

Allyson Waller. The Ohio State University College of Pharmacy. 2016 – 2021
Project(s): Gemcitabine plus liposomal doxorubicin for relapsed refractory T-cell lymphomas
International Conference on Malignant Lymphoma; ICML Lugano Abstract
Manuscript in Preparation

Carlo Legasto. The Ohio State University College of Pharmacy. 2016 – 2017
Project(s): Romidepsin for the Treatment of Relapsed and Refractory T-Cell Lymphomas: A Single-Center Experience
Manuscript in preparation

Advanced Practice Registered Nurses

Cara Grantier, CNP, APRN. The Ohio State University James Cancer Hospital. 2018 – 2021
Project(s): Quality of Life in Cutaneous T-Cell Lymphoma Subjects Treated with Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from the Phase 3 MAVORIC Trial
Oncology Nursing Society's Annual Conference Poster

Junior Faculty

<u>Sabarish Ayyappan</u> . The Ohio State University College of Medicine. Current position: Assistant Professor of Internal Medicine (University of Iowa) Project: Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy <i>Review published Curr Oncol Rep. 2018</i>	2017 – 2018
<u>Narendranath Epperla</u> . The Ohio State University College of Medicine. Current position: Assistant Professor of Internal Medicine - Hematology (OSU) Project: Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib <i>Review article –published in Cancer Management and Research 2018</i>	2017 – 2018
<u>John Reneau</u> . The Ohio State University College of Medicine. Current position: Assistant Professor of Internal Medicine - Hematology (OSU) Project(s): 1. Letermovir for cytomegalovirus prophylaxis in patients with hematological malignancies treated with alemtuzumab (<i>Study open to accrual</i>) 2. A Phase I/II, open label, trial of <CONFIDENTIAL> in combination with standard dose EPOCH chemotherapy for front line therapy of peripheral T cell lymphoma (<i>study abandoned by sponsor</i>) 3. Phase I trial of <CONFIDENTIAL> in CTCL (<i>LOI</i>) 4. Randomized phase II trial of <CONFIDENTIAL> in moderate to severe COVID-19 infection (<i>Pre-IND</i>) 5. A multisite, phase I/II trial evaluating the combination of <CONFIDENTIAL> and gemcitabine for the treatment of relapsed and refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (<i>protocol in development</i>)	2019 – 2021

Honors and Awards

Knight Commander, Order of St Ignatius of Antioch	2025
Knight Grand Cross, The Holy Orthodox Order of Saint George the Great Martyr	2025
Nominated for Full Membership in Sigma Xi, The Scientific Research Honor Society	2025
Nominated as Castle Connolly Top Doctor	2024/2025
John P. McConnell Endowed Chair for Cancer Research, OhioHealth Foundation	2023
Top Decile of Patient Experiences in FY2019	2020
Fellow of the American College of Physicians (FACP)	2015
Patient safety champion, University Hospitals Case Medical Center	2014
Fellow Research Award, University of Nebraska Medical Center, Department of Internal Medicine	2012
Conquer cancer foundation Oncology trainee travel award to attend the American Society of Clinical Oncology (ASCO) meeting	2011
American Society of Hematology (ASH) travel award to attend the ASH meeting	2010
Doctor of Medicine degree (M.D.), The State Education Department The State University of New York, Albany, NY	2010
AMA Physician's Recognition Award (PRA) with commendation	2007
Certificate of merit for outstanding poster presentation, American College of Physicians	2004
Grant from the Johns Hopkins University School of Medicine to enroll in the Graduate Program in Pathobiology, Baltimore, MD	1999
Graduated with Honors from Faculty of Medicine , Ains Shams University, Cairo Egypt	1996

Grants and Contract Awards

Current Research Support

John P. McConnell Endowed Chair for Cancer Research, OhioHealth Foundation 11/2023-

OhioHealth endowed chairs are essential to achieving excellence in OhioHealth mission and are made possible through philanthropic support. The McConnell family and the McConnell Foundation have generously provided the funds to conduct research, groundbreaking clinical trials, explore new treatments and offer educational opportunities to our cancer care physicians

COMPLETED RESEARCH SUPPORT

Pelotonia Intramural Grants William >> Vasu (PI) 7/1/2020 – 6/30/2022

A pilot phase I trial of IL-21 expanded, off the shelf, third-party natural killer (NK) cells in combination with mogamulizumab in patients with Cutaneous T-cell Lymphomas or Adult T-cell Leukemia/Lymphomas
Role: PI (no salary support)

ACS IRG-91-022-18 William (PI) 1/1/14-12/31/14

Modulation of graft versus leukemia (GVL) and graft versus host (GVH) responses by oral azacitidine
hypomethylating therapy after allogeneic stem cell transplantation (SCT); An ancillary correlative science study. This is a correlative science project associating a novel phase I/II trial of oral azacitidine maintenance for patients with myelodysplastic syndrome or acute myeloid leukemia after allogeneic HSCT aimed at studying the pharmacodynamics, and pharmacodynamic/pharmacokinetic interactions, of oral azacitidine maintenance after HSCT, the impact of oral azacitidine after SCT on minimal residual disease (MRD) as the most sensitive determinant of effectiveness, and allogeneic immune recovery after HSCT while on oral azacitidine.

NCI Early Phase Clinical Research Support Award William (PI) 10/16/14-10/15/16

CASE 9513: A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage

Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). This was a novel phase II clinical trial aimed at determining the efficacy, and tolerability, of curcumin and vitamin D3 combination in patients with untreated (early stage) CLL and/or SLL. There is a built in correlative science project aiming at determining the mechanism of action and, potentially synergy, of curcumin and vitamin D3 and not study pharmacodynamics/pharmacokinetic correlations of such regimen.

GRANTS SUBMITTED BUT NOT FUNDED

PAR-18-559 (NCI) Zick, Suzanna (PI) 07/01/2021 - 06/30/2026

The Fatigue Reduction Diet Clinical Trial: Looking for self-care interventions for diverse groups of fatigued cancer survivors

Goals - to study the role of a fatigue reducing diet in patients with diffuse large B-cell lymphoma and breast cancer.

Role: Co-Investigator (2% effort)

TBD (DOD) Zick, Suzanna (PI) 09/30/2021 - 09/29/2024

Living Well with Lymphoma: Improving diet quality to improve energy, sleep and quality of life
Goals - to study the role of a fatigue reducing diet in patients with diffuse large B-cell lymphoma.

Role: Co-Investigator (2% effort) Pending Research Support

TBD (Gateway for Cancer Research) William (PI) 4/1/2020 – 3/31/2022

A phase I study evaluating the safety and efficacy of <CONFIDENTIAL> in combination with gemcitabine in T-cell lymphomas

Role: PI (10% effort)

TBD (DOD) Kim, Sanggu (PI) 4/1/2020 – 3/31/2022

Targeted antibody and immunotoxin combination therapy for T-cell lymphoma

Goals - to develop a novel antibody and immunotoxin combination therapy to improve survival rates for T-cell lymphoma patients.

Role: Co-Investigator (5% effort)

(Leukemia & Lymphoma Society) William (PI) 4/1/2020 – 3/31/2022

Pilot trial of IL-21 expanded natural killer (NK) cells and mogamulizumab in T-cell Lymphomas
Goals - to develop a pilot phase I trial with an expansion cohort, of 16-19 patients, testing the safety and efficacy of IL-21 expanded, off the shelf, third-party natural killer (NK) cells in combination with mogamulizumab in patients with T-cell Lymphomas including cutaneous and peripheral T-cell lymphomas and adult T-cell leukemia lymphoma
Role: PI (8% effort)

R01 CA215495-01A1 (NIH) Mishra, Anjali (PI) 05/01/2018 - 04/30/2023

Elucidating the role of inflammation in the genesis and propagation of cancer.

Goals –To dissect the regulation of IL-15 and downstream effectors in T-cell lymphomagenesis.
Priority Score: 20 (reviewed at Molecular Oncogenesis Study section)
Role: Co-Investigator (5% effort)

Gabrielle's Angel Foundation William (PI) 05/01/2019 - 04/30/2022

Curcumin and vitamin D combination to improved quality of life in patients with cutaneous Tcell lymphoma: a clinical/translational study

Cutaneous T-cell lymphomas (CTCL) is a group of diseases that involve the skin causing burning, pruritus, and significant impairment of quality of life. Curcumin (CM) and vitamin D (VD) are safe and inexpensive agents that were well-tolerated in our recently completed trial in early stage chronic lymphocytic leukemia. Data generated by us and others showed the cytotoxic effect of both agents in CTCL cells lines. We hereby propose a translational investigation of the efficacy of CM-VD combination in the murine model of CTCL to examine mechanism of synergy in parallel with an open-label phase II trial of 29 patients with CTCL.

1U19AI117933-0 Zaia, John and Gerson, Stanton (PI) 03/01/2015- 02/29/2020

Engineering and evaluation of stem cell grafts for HIV-1 gene therapy.

Goals – This program is a collaboration of HIV-1 biologists, immunologists, transplant physicians, and stem cell engineers from academia and industry, namely, City of Hope, Case Western Reserve University, and Angiocrine Bioscience, is to develop and test in humans an improved therapy for HIV that would, if successful, control the infection without antiretroviral therapy. The novelty of this strategy is that it combines improved methods of cell engineering that would allow processing of blood stem cells from AIDS patients in a way that makes them and the resultant immune system resistant to HIV infection. When completed, the project would yield an HIV cure that is safe, economical and scalable to a large numbers of patients.

Role: Co-Investigator (10% effort y1-3 20% effort y4-5)

Description: I designed the pilot clinical trial to transplant autologous hematopoietic progenitor cells that we designed in y1-3 to be resistant to HIV. I was the proposed PI of that clinical trial planned for y4-5 of the project grant.

RECENT CLINICAL TRIALS (Principal Investigator at OhioHealth Bing Cancer Center/Riverside Methodist Hospital) -

Protocol No.	Title	Current Status
IELSG52	Integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma.	PENDING
USCLC Registry	USCLC National Cutaneous Lymphoma Registry Research Protocol	PENDING
PETAL CONSORTIUM	PETAL Consortium- Integration of machine learning and genomics to predict outcomes for newly diagnosed, relapsed and refractory mature T-cell and NK-cell neoplasms: a global study of the PETAL Consortium	OPEN TO ACCRUAL
SPI-BEL-301	A Phase 2/3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-	OPEN TO ACCRUAL

	CHOP or Folutyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma	
EA4232 / PTCL-STAT	A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) ALLIANCE CO-CHAIR FOR TRIAL	OPEN TO ACCRUAL
BP41072	An open-label, phase I/II study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of engluma-fusp alfa (RO7227166, a CD19 targeted 4-1BB ligand) in combination with obinutuzumab and in combination with glofitamab following a pre-treatment dose of obinutuzumab administered in participants with relapsed/refractory b-cell non-Hodgkin's lymphoma	CLOSED TO ACCRUAL
BGB-11417-302	A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma	OPEN TO ACCRUAL
QuANTUM-Wild	A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD (-) Acute Myeloid Leukemia	OPEN TO ACCRUAL
A051902	A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas	OPEN TO ACCRUAL
M20-621	A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma	CLOSED TO ACCRUAL
M23-362	A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting	CLOSED TO ACCRUAL
1066995-3	NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study	PENDING ACTIVATION
1884847-5	A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)	SUSPENDED
1912388-2	REAL-MIND: Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant	CLOSED TO ACCRUAL
2039484	AB-101-01: A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin	CLOSED TO ACCRUAL
2101606	A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera	CLOSED TO ACCRUAL

1930392	XPORT-MF-034: A phase 1/2 study to evaluate safety and efficacy of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment naive patients with myelofibrosis	CLOSED TO ACCRUAL
---------	---	-------------------

PRIOR CLINICAL TRIALS (Principal Investigator at OSU-James Comprehensive Cancer Center) -

Protocol No.	Title
OSU-16161	A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
OSU-17117	A Phase II Multicenter Study Of Axicabtagene CiloleuceL In Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (INHL)
OSU-17204	A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
OSU-17225	A phase I/II trial of Venetoclax and BEAM conditioning followed by autologous stem cell transplantation for patients with primary refractory non-Hodgkin lymphoma
OSU-18244	SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
OSU-18370	PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study
OSU-19005	Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
OSU-12160	A Phase 1 Study of IPI-145 in Patients with Advanced Hematologic Malignancies
OSU-12197	Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
OSU-14271	A Phase 2 Study of MK-3475 for the treatment of Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome
OSU-15066	A Multicenter Phase 1 Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
OSU-15182	A Phase I dose-ranging study to investigate the safety, tolerability, and pharmacokinetics of MRG-106 following local intratumoral and subcutaneous injection in patients with cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) sub-type

OSU-16172	A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
OSU-18331	CART (Tisagenlecleucel) IPR Reinfusion for an Individual Patient Previously Infused with Tisagenlecleucel
OSU-13015	A randomized, double-blind, placebo-controlled, phase 3 study of CH-P and brentuximab vedotin versus CHOP in the front-line treatment of patients with CD30-positive mature T-cell lymphomas
OSU-15221	Open label, multicenter phase I study of IPH4102, a humanized anti-KIR3DL2 monoclonal antibody, in patients with relapsed/refractory cutaneous T-cell lymphomas (CTCL)

CLINICAL TRIALS (CO-INVESTIGATOR AT OSU-JAMES COMPREHENSIVE CANCER CENTER)

Protocol No.	Title	PI Name
2017H0069	A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease (BMT in SCD, STRIDE)	Desai, Payal, C
ALLIANCE-A031102	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, And Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment In Relapsed Or Refractory Germ Cell Tumors	Monk, J. Paul
ALLIANCE-A051301	A Randomized Double-Blind Phase III Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype	Jaglowksi, Samantha, M
ALLIANCE-A061202	A Phase I/II Study Of Pomalidomide, Dexamethasone And Ixazomib Vs. Pomalidomide And Dexamethasone For Patients With Multiple Myeloma Refractory To Lenalidomide And Proteasome Inhibitor-Based Therapy	Efebera, Yvonne, A
AMC-095	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Tumors with an Expansion Cohort in HIV Associated Solid Tumors	Baiocchi, Robert
AMC-098	A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma A Trial of the AIDS Malignancy Consortium (AMC)	Baiocchi, Robert
AMC-101	A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas	Baiocchi, Robert
BMT-CTN1702	Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation	Saad, Ayman

BMT-CTN1703	A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation	Efebera, Yvonne, A
BMT-CTN1704	Composite Health Assessment Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM)	Wall, Sarah, A
BMT-CTN1801	A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation	Efebera, Yvonne, A
ECOG-ACRIN-EA4151	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission	Maddocks, Kami
ECOG-ACRIN-EA4181	A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma	Maddocks, Kami
OSU-11002	Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease	Efebera, Yvonne, A
OSU-11087	A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications	Vasu, Sumithira
OSU-13219	A Feasibility Study of Organ-Sparing Marrow-Targeted Irradiation (OSMI) to Condition Patients with High-risk Hematologic Malignancies Prior to Allogeneic Hematopoietic Stem Cell Transplantation	Welliver, Meng, X
OSU-13248	Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository	Choe, Hannah, K
OSU-14087	A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	Woyach, Jennifer, A
OSU-15029	An Open-label, Phase Ib/II Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma	Christian, Beth, A

OSU-15270	Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease	Efebera, Yvonne, A
OSU-16040	A Phase Ib, Multicenter, Open-label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma	Maddocks, Kami
OSU-16077	A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma	Alinari, Lapo
OSU-16135	Long-Term Follow-Up Study Of Clinical Study Subjects Treated With Actr087, Autologous T Cells Expressing Antibody- Coupled T-Cell Receptors	Jaglowski, Samantha, M
OSU-16142	A Pilot Study Of Ny-Eso-1c259t Cells In Subjects With Advanced Myxoid/ Round Cell Liposarcoma	Liebner, David, A
OSU-16152	A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia	Choe, Hannah, K
OSU-16167	A Phase I/II Study of the PD-1 Antibody Nivolumab in Combination with Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD)	Maddocks, Kami
OSU-16242	Romidepsin Therapy in Conditioning and Maintenance in Patients with T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant	Brammer, Jonathan, E
OSU-17007	A Phase II Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)	Jaglowski, Samantha, M
OSU-17059	A Phase II, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma	O'Malley, David
OSU-17063	A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies	He, Kai
OSU-17072	A Phase I Dose Escalation, Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)	He, Kai
OSU-17076	Phase I Study of Venetoclax plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas	Maddocks, Kami
OSU-17092	A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies	Jaglowski, Samantha, M
OSU-17101	Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes	Vasu, Sumithira

OSU-17102	Phase I/II clinical trial of Daratumumab and donor lymphocyte infusion in patients with relapsed acute myeloid leukemia post-allogeneic hematopoietic stem cell transplant	Vasu, Sumithira
OSU-17111	A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies	Woyach, Jennifer, A
OSU-17130	A Multicenter, Open-Label, Expanded Access Study Of Axicabtagene Ciloleucel For The Treatment Of subjects with Relapsed/Refractory Large B-Cell Lymphoma	Jaglowski, Samantha, M
OSU-17152	A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies	Woyach, Jennifer, A
OSU-17170	Phase I Study of ACTR707, an Autologous T Cell Product, in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma	Jaglowski, Samantha, M
OSU-17199	Pilot study of Haploidentical Donor Cytomegalovirus (CMV) Specific Cytotoxic T-lymphocytes (CTL) to Treat CMV Reactivation or Infection after Solid Organ and Hematopoietic Stem Cell Transplantation (HCT)	Vasu, Sumithira
OSU-17235	A Phase Ib/II Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease	Saad, Ayman
OSU-17239	A Phase I Dose-Escalation Study Of The Selective PKC-beta Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Blachly, James, S
OSU-17273	A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients with Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma	Brammer, Jonathan, E
OSU-17344	A Phase Ib/II Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies	Brammer, Jonathan, E
OSU-17357	Phase II Study of Maintenance Ruxolitinib after Allogeneic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)	Vasu, Sumithira
OSU-18023	A Phase II Study of Palbociclib (PD-0332991) in Combination with Ibrutinib in Patients with Previously Treated Mantle Cell Lymphoma	Maddocks, Kami

OSU-18035	Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)	Baiocchi, Robert
OSU-18055	FITNESS: Calculating risk of chemotherapy toxicity in older adults	Rosko, Ashley, E
OSU-18066	A Multi-Center, Phase II, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	Brammer, Jonathan, E
OSU-18078	Single, High Dose Vitamin A Replacement in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Choe, Hannah, K
OSU-18084	A Multi-Center Phase II Trial of Ibrutinib plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma	Maddocks, Kami
OSU-18173	A Phase I Study of Duvelisib in Combination with Nivolumab for Patients with Richter's Syndrome and Transformed Follicular Lymphoma	Woyach, Jennifer, A
OSU-18183	A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas	Brammer, Jonathan, E
OSU-18195	A Phase I Multidose Study to Evaluate the Safety and Tolerability of Xmab 13676 in Patients with Cd20-Expressing Hematologic Malignancies	Byrd, John
OSU-18213	A Phase I Study of IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms following Allogeneic Stem Cell Transplantation	Mims, Alice, S
OSU-18224	Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Large B-Cell Lymphoma Patients with Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel out of Specification for Commercial Release	Jagowski, Samantha, M
OSU-18249	The Ohio State University Graft Versus Host Disease (GVHD) Biorepository	Choe, Hannah, K
OSU-18250	Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease	Choe, Hannah, K
OSU-18281	A Phase II Study of Nivolumab in Combination with DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma	Bond, David, A
OSU-18282	A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease after Failure of Systemic Glucocorticoids	Saad, Ayman
OSU-18297	Phase I, Multicenter, Open-Label Study of the Antibody-Drug Conjugate Trph-222 in Subjects with Relapsed and/or Refractory B-Cell Lymphoma	Christian, Beth, A

OSU-18303	A Phase 1 Study of an Autologous ACTR T Cell Product in Combination with Trastuzumab, a Monoclonal Antibody, in Subjects with HER2-Positive Advanced Malignancies	Wesolowski, Robert
OSU-18307	A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)	Woyach, Jennifer, A
OSU-18330	A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis	Wall, Sarah, A
OSU-18348	A Phase II, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors	He, Kai
OSU-18374	A Phase 1 Open-Label, Multicenter, Dose Escalation Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies	Baiocchi, Robert
OSU-19029	A Phase I Study of IDH1 Inhibition using Ivosidenib as Maintenance Therapy for IDH1- Mutant Myeloid Neoplasms following Allogeneic Stem Cell Transplantation	Mims, Alice, S
OSU-19034	A Phase 1, dose escalation and expansion study of engineered donor grafts derived from mobilized peripheral blood (OrcaGraft), with single agent graft-versus-host disease prophylaxis, in recipients undergoing myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies	Saad, Ayman
OSU-19071	A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NYESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer	He, Kai
OSU-19074	A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma	Maddocks, Kami
OSU-19101	An Open Label, Non-Randomized Multicenter Phase 2b, Study with a Safety Run-in to Evaluate the Safety and Efficacy of RGI-2001 for the Prevention of Acute Graft-Versus-Host Disease (aGvHD) Compared to Contemporary Controls in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)	Efebera, Yvonne, A
OSU-19130	A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma	Liebner, David, A

OSU-19143	A Phase II, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma	Maddocks, Kami
OSU-19178	A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma	Reneau, John
OSU-19179	A Phase I/II Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Long, Meixiao
SWOG-S1608	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma	Maddocks, Kami
SWOG-S1826	A Phase III, Randomized Study of Nivolumab (Opdivo) Plus Avd or Brentuximab Vedotin (Adcetris) Plus Avd in Patients (Age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma	Maddocks, Kami

Prior Clinical trials (Principal Investigator at University Hospitals Case Medical Center)

1. A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients
2. A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia to Evaluate the Benefit of GDC-0199 (ABT-199) plus Rituximab Compared with Bendamustine plus Rituximab
3. A Phase 2 Open-Label Study of the Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion
4. A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
5. A Phase 3, Multicenter, Randomized, Doubleblind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia Due to IPSS Lower- Risk Myelodysplastic Syndromes
6. A Phase 1/2, Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (Cc-486) In Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
7. Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients with Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
8. Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
9. Targeting of the Leukemia Stem Cell Population with Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML
10. Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

Publications

1. **William BM**, Abdel-tawab AM, Hassan EA, Mohamed, OF (2004): Acetylator Phenotyping in patients with malignant lymphomas, using Caffeine as the Metabolic Probe. Polish Journal of Pharmacology; 56(4):445-449 2004

2. **William BM**, Corazza GR (2007): Hyposplenism: A Comprehensive Review Part I; Basic Concepts and Causes. *Hematology*; 12(1):1-13 2007
3. **William BM**, Thawani N, Sae-Tia S, Corazza GR (2007): Hyposplenism: A Comprehensive Review Part II; Clinical manifestations, diagnosis, and management. *Hematology*; 12(2):89-98 2007
4. **William BM** Adjunctive role for recombinant activated factor VII (rFVII) in the Treatment of bleeding secondary to a factor V inhibitor. *Blood coagulation and fibrinolysis*; 19(4):327–328 2008
5. **William BM**, Goodrich A, Peng C, Li S (2008): Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing p210-BCR-ABL or T315I- BCR-ABL and prolongs survival of mice with B-Cell Acute Lymphoblastic Leukemia. *Hematology*; 13(6):333-343 2008
6. **William BM** (2009): Hyposplenism associating long-term asbestos exposure. *Romanian Journal of Internal Medicine*; 47(4):415-6 2009
7. **William BM** and Bierman PJ (2010): I-131 tositumomab. *Expert Opinion on Biological Therapy*; 10(8):1271-8. 2010
8. **William BM** and Grem JL (2011): Brain Metastasis and Leptomeningeal Carcinomatosis in a Patient with Cholangiocarcinoma. *Gastrointestinal Cancer Research*; 4(4):144-5. 2011
9. **William BM**, Harbert T, Ganti AK, Bierman PJ (2011): Small lymphocytic lymphoma in a patient with CREST syndrome. *Hematology/Oncology and Stem Cell Therapy*; 4(3): 132-135 2011
10. **William BM**, Bongu NR, Bast MA, Bociek RG, Bierman PJ, Vose JM, Armitage JO (2013): The utility of serum lactate dehydrogenase (LDH) in the follow-up of patients with diffuse large B-cell lymphoma (DLBCL). *Brazilian Journal of Hematology and Hematotherapy*; 35(3):189-91. 2013
11. **William BM**, Loberiza FR, Whalen V, Bierman PJ, Bociek RG, Vose JM, Armitage JO (2013): Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation (ASCT) for Hodgkin lymphoma. *Clinical Lymphoma Myeloma & Leukemia*; 13(4): 417-23. 2013
12. **William BM**, Armitage JO (2013): International analysis of the frequency and outcomes of NK/T- cell lymphomas. *Best Practice & Research Clinical Haematology*; 26(1):23-32. 2013
13. Bashir Q, **William BM**, Garcia-Manero G, de Lima M (2013). Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. *Rev Bras Hematol Hemoter*; 35(2):126-33. 2013
14. **William BM**, de Lima MJ (2013): Advances in Conditioning Regimens for Older Adults undergoing Allogeneic Stem Cell Transplantation to Treat Hematologic Malignancies. *Drugs & Aging*; 30(6):373-81. 2013
15. **William BM**, de Lima M (2014). Sirolimus plus calcineurin inhibitors and methotrexate; is more necessarily better? *Leukemia Lymphoma*; 27:1-5. 2014
16. Massoud MR, **William BM**, Harrill K, Cooper BW, de Lima M, Schmaier AH (2014): Transmission of lupus anticoagulant by allogeneic stem cell 2014

transplantation. *Brazilian Journal of Hematology and Hematotherapy*; 36(4):287-9.

17. **William BM**, Allen MS, Loberiza FR, Bociek RG, Bierman PJ, Armitage JO and Vose JM (2014): Phase I/II Study of VELCADE®-BEAM (V-BEAM) and Autologous Hematopoietic stem cell transplantation (ASCT) for relapsed indolent non-Hodgkin's lymphoma (NHL), Transformed or Mantle Cell Lymphoma (MCL). *Biology of Blood and Marrow Transplantation*; 20(4):536-42. 2014
18. **William BM** (2015). Azacitidine and allogeneic stem cell transplantation; when and why? *Acta Haematologica*; 134(1):38-9 2015
19. Afable M, Caimi PF, Hosing C, de Lima M, Khouri IF, **William BM**, Nieto Y, Cooper BW, Anderlini P, Campagnaro EL, Gerson SL, Lazarus HM, Champlin RE, Popat UR (2015): Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant. *Biology of Blood and Marrow Transplantation*; 21(8):1529-31 2015
20. Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, **William BM**, Wirk B, Maloney DG, Smith MS, Sureda AM, Carreras J, Hamadani M (2015): Impact of "real-world" interpretation of pre-transplant FDG-PET status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. *Biology of Blood and Marrow Transplantation*; 21(9):1605-11 2015
21. Caimi PF, **William BM**, Silva CH, Fu P, Cooper BW, Campagnaro EL, Gerson SL, Reese-Koc J, Fox R, Creger RJ, De Lima M, Lazarus HM (2015): Comparison of two BCNU - containing regimens in the Rituximab era. Excellent outcomes even in poor risk patients. *Biology of Blood and Marrow Transplantation*; 21(11):1926-31 2015
22. Al-Kindi SG, Abu-Zeinah GF, Kim CH, Hejjaji V, **William BM**, Caimi PF, Oliveira GH (2015): Trends and Disparities in Cardiovascular Mortality Among Survivors of Hodgkin Lymphoma. *Clinical Lymphoma, Myeloma & Leukemia*; 15(12):748-752 2015
23. **William BM**, An W, Feng D, Nadeau S, Mohapatra BC, Storck MA, Band V, Band H (2016): Fasudil, a clinically-safe ROCK Inhibitor, Decreases Disease Burden in a Cbl/Cbl-b Deficiency- Driven Murine Model of Myeloproliferative Disorders. *Hematology*; 21(4):218-24 2016
24. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, **William BM** (2016): Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. *British Journal of Haematology*; 173(3):404-12 2016
25. Hambley B, Caimi PF, **William BM** (2016): Bortezomib for the treatment of mantle cell lymphoma. An update. *Therapeutic Advances in Hematology*; 7(4):196-208 2016
26. Shaffer B, Ahn KW, Hu Z, Nishihori T, Malone A, Valcarcel D, Grunwald M, Bacher U, Hamilton B, Kharfan-Dabaja M, Saad A, Cutler C, Warlick E, Reshef R, Wirk B, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood W, Costa L, Miller A, 2016

- Cortes J, Daly A, Kindwall-Keller T, Kamble R, Rizzieri D, Cahn JY, Gale R, **William BM**, Litzow M, Wiernik P, Liesveld J, Savani B, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W (2016): A Scoring System Prognostic of Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. *Journal of Clinical Oncology*; 34(16):1864-71
27. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, **William BM** (2016): Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. *British Journal of Haematology*; 175(2):275-280 2016
 28. Massoud MR, Caimi PF, Ferrari N, Fu P, Creger R, Fox R, Carlson-Barko J, Kolk M, Brister L, Cooper BW, Gerson S, Lazarus HM, de Lima M, **William BM** (2016): Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience. *Brazilian Journal of Hematology and Hemotherapy*; 38(4):314-319. 2016
 29. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, **William BM** (2017): Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. *Hematology*; 22(7):405-411 2017
 30. Eulitt P, Fabian D, Kelly C, Hemminger J, **William BM** (2017): Waldenström's macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125. *Hematol Oncol Stem Cell Ther*. S1658-3876(17)30034-1 2017
 31. Caimi PF, Cooper BW, **William BM**, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL (2017): Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. *Oncotarget*; 8(45):79864-79875 2017
 32. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, **William B**, Wirk BM, Krishnan A, Nieto Y, D'Souza A (2017): Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. *Bone Marrow Transplant* 52(12):1616-1622 2017
 33. **William BM**, Wang T, Haagenson MD, Fleischhauer K, Verneris M, Hsu KC, de Lima MJ, Fernandez-Viña M, Spellman SR, Lee SJ, Hill BT (2017): Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. *Biol Blood Marrow Transplant*; pii: S1083-8791(17)30817-0. doi: 10.1016/j.bbmt.2017.11.003. [Epub ahead of print] 2017
 34. Kohnken R, Wen J, Mundy-Bosse B, McConnell K, Keiter A, Grinshpun L, Hartlage A, Yano M, McNeil B, Chakravarti N, **William B**, Bradner JE, Caligiuri MA, Porcu P, Mishra A (2017): Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. *Blood*; 131:771-781 2017
 72. Casulo C, Friedberg JW, Woo Ahn K, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen A, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, 2017

- Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, **William B**, Cumpston A, Zelenetz AD, Link BK, Hamadani M (2017): Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. *Biol Blood Marrow Transplant*; pii: S1083-8791(17)31675-0. doi: 10.1016/j.bbmt.2017.12.771. [Epub ahead of print]
36. Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, **William B**, Zain J, Dwyer MA, Sundar H (2018): NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. *J Natl Compr Canc Netw*. 2018 Feb;16(2):123-135. 2018
37. Richardson DR, Huang Y, McGinty HL, Elder P, Newlin J, Kirkendall C, Andritsos L, Benson D, Blum W, Efebera Y, Penza S, Hofmeister C, Jaglowski S, Klisovic R, Vasu S, **William B**, Devine S, Rosko AE (2018): Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. *Bone Marrow Transplant*. 2018 Feb 14. [Epub ahead of print] 2018
38. Ayyappan S and **William BM** (2018): Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy. *Current Oncology Reports*. 2018 Mar 23;20(4):33 2018
39. Denlinger NM, Epperla N, **William BM** (2018): Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. *Cancer Management and Research* 27; 10:615-624 2018
40. Kunati SR, Yang S, **William BM**, Xu Y. An LC-MS/MS method for simultaneous determination of curcumin, curcumin glucuronide and curcumin sulfate in a phase II clinical trial. *J Pharm Biomed Anal*. **2018 Jul** 15;156:189-198. doi: 10.1016/j.jpba.2018.04.034. Epub 2018 Apr 23. PMID: 29727780 2018
42. Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnen R, Lee DA, Lozanski G, Freud AG, Porcu P, **William B**, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. *Blood Adv*. **2018 Aug** 14;2(15):1818-1827. doi: 10.1182/bloodadvances.2018020388. No abstract available. PMID: 30054309 2018
41. Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, Yang S, Wu H, Bostic M, Jaglowski S, Brammer JE, **William B**, Choe H, Mims AS, Penza S, Efebera Y, Devine S, Cataland S, Davies SM, Vasu S. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. *Blood Adv*. **2018 Oct** 23;2(20):2619-2628. doi: 10.1182/bloodadvances.2018020321. PMID: 30327370 2018
42. de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, **William BM**, Hetzer J, Laille E, Hubbell B, Skikne BS, Craddock C. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. *Biol Blood Marrow Transplant*. **2018 Oct**;24(10):2017-2024. doi: 10.1016/j.bbmt.2018.06.016. Epub 2018 Jun 20. PMID: 29933073 2018
43. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, 2018

- Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, **William BM**, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk Of Acute Myeloid Leukemia And Myelodysplastic Syndrome After Autotransplants For Lymphomas And Plasma Cell Myeloma. *Leuk Res*. **2018 Nov**;74:130-136. Doi: 10.1016/J.Leukres.2018.07.016. Epub 2018 Jul 19. PMID: 30055822
44. Richardson DR, Huang Y, McGinty HL, Elder P, Newlin J, Kirkendall C, Andritsos L, Benson D, Blum W, Efebera Y, Penza S, Hofmeister C, Jaglowski S, Klisovic R, Vasu S, **William B**, Devine S, Rosko AE. Psychosocial Risk Predicts High Readmission Rates for Hematopoietic Cell Transplant Recipients. *Bone Marrow Transplant*. 2018 Nov;53(11):1418-1427. doi: 10.1038/s41409-018-0118-4. Epub 2018 Feb 14. PMID: 29445123
45. Ueda M, El-Jurdi N, Cooper B, Caimi P, Baer L, Kolk M, Brister L, Wald DN, Otegbeye F, Lazarus HM, Sandmaier BM, **William B**, Sauntharajah Y, Woost P, Jacobberger JW, de Lima M. Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse. *Biol Blood Marrow Transplant*. 2019 Jun;25(6):1122-1127. doi: 10.1016/j.bbmt.2018.12.764. Epub **2018 Dec** 30. PMID: 30599207
46. Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, **William BM**, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA. BEAM Or BUCYVP16-Conditioning Regimen For Autologous Stem-Cell Transplantation In Non-Hodgkin's Lymphomas. *Bone Marrow Transplant*. **2019 Feb** 4. doi: 10.1038/s41409-019-0463-y. [Epub ahead of print] PMID: 30718797
47. Yucebay F, Matthews C, Puto M, Li J, **William B**, Jaglowski SM, Penza SL, Vasu S, Benson DM, Andritsos LA, Devine SM, Efebera YA, Roddy JVF. Tocilizumab as First Line Therapy For Steroid-Refractory Acute Graft-Versus-Host-Disease: Analysis Of A Single-Center Experience. *Leuk Lymphoma*. **2019 Feb** 15:1-7. Doi: 10.1080/10428194.2019.1573996. [Epub Ahead Of Print] PMID: 30764681
48. Kohnken R, McNeil B, Wen J, McConnell K, Grinshpun L, Keiter A, Chen L, **William B**, Porcu P, Mishra A. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma. *J Invest Dermatol*. 2019 Sep;139(9):1966-1974.e3. doi: 10.1016/j.jid.2019.01.033. Epub **2019 Mar** 12. PMID: 30876800
49. Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, **William BM**, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM. Phase I/II Study Of Dasatinib And Exploratory Genomic Analysis In Relapsed Or Refractory Non-Hodgkin Lymphoma. *Br J Haematol*. 2019 Mar;184(5):744-752. Doi: 10.1111/Bjh.15702. Epub **2018 Dec** 5. PMID: 30520026
50. Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS,

Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, **William B**, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S. Impact of T-Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. *Biol Blood Marrow Transplant.* **2019 May** 11. pii: S1083-8791(19)30291-5. doi: 10.1016/j.bbmt.2019.05.007. [Epub ahead of print] PMID: 31085303

51. Issa H, Sharma N, Zhao Q, Ruppert AS, Elder P, Benson DM, Penza S, Vasu S, **William B**, Jaglowski S, Devine SM, Efebera YA. Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* **2019 Jun** 20. pii: S1083-8791(19)30378-7. doi: 10.1016/j.bbmt.2019.06.014. [Epub ahead of print] PMID:31229641 2019
52. **S**inger S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, **William BM**, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. *Biol Blood Marrow Transplant.* **2019 Jun**; 25(6):1107-1115. doi: 10.1016/j.bbmt.2019.01.032. Epub 2019 Feb 1.PMID:30716453 2019
53. Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, **William B**, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu S. Transplant-Associated Thrombotic Microangiopathy: Is The Treatment More Expensive Than The Disease? *Bone Marrow Transplant.* **2019 Jun**;54(6):913-916. Doi: 10.1038/S41409-018-0390-3. Epub 2018 Nov 9. No Abstract Available. PMID: 30413812 2019
54. Bagot M, Porcu P, Marie-Cardine A, Battistella M, **William BM**, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafoos C, Sicard H, Azim HA Jr, Kim YH. IPH4102, A First-In-Class Anti-KIR3DL2 Monoclonal Antibody, In Patients With Relapsed Or Refractory Cutaneous T-Cell Lymphoma: An International, First-In-Human, Open-Label, Phase 1 Trial.*Lancet Oncol.* **2019 Jun** 25 [Epub Ahead Of Print] 2019
55. Ustun C, Kim S, Chen M, Beitinjane AM, Brown VI, Dahi PB, Daly A, Diaz MA, Freytes CO, Ganguly S, Hashmi S, Hildebrandt GC, Lazarus HM, Nishihori T, Olsson RF, Page KM, Papanicolaou G, Saad A, Seo S, **William BM**, Wingard JR, Wirk B, Yared JA, Perales MA, Auletta JJ, Komanduri KV, Lindemans CA, Riches ML. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. *Blood Adv.* **2019 Sep** 10;3(17):2525-2536. doi: 10.1182/bloodadvances.2019000226. PMID: 31471322 [PubMed - in process] 2019
56. Tomlinson BK, Gallogly MM, Kane DM, Metheny L, Lazarus HM, **William BM**, Craig MD, Levis MJ, Cooper BW.A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. *Clinical Lymphoma Myeloma Leuk.* **2019 Nov** 6. pii: S2152-2650(19)32096-8. doi: 10.1016/j.clml.2019.10.018. [Epub ahead of print] PMID: 32085993 [PubMed - as supplied by publisher] 2019
57. Abbasi A, Chung C, **William BM**. Dramatic and Durable 2019

Responses to Romidepsin in Two Patients With the Lymphocytic Variant of Hypereosinophilic Syndrome. *Clin Lymphoma Myeloma Leuk*. **2019 Nov 9**. pii: S2152-2650(19)32103-2. doi: 10.1016/j.clml.2019.11.006. [Epub ahead of print] PMID: 32035786

58. Vu K, Wu CH, Yang CY, Zhan A, Cavallone E, Berry W, Heeter P, Pincus L, Wieduwilt MJ, **William BM**, Andreadis C, Kaplan LK, McCormick F, Porcu P, Brammer JE, Ai WZ. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. *Clin Cancer Res*. **2019 Nov 26**. doi: 10.1158/1078-0432.CCR-19-2152. [Epub ahead of print] PMID: 31772119
59. Hwang S, Johnson A, Fabbro S, Hastings J, Haverkos B, Chung C, Porcu P, **William BM**: Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience. *Br J Dermatol*. Accepted Author Manuscript. doi:10.1111/bjd.18961
60. Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, **William B**, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK: Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. *Biol Blood Marrow Transplant*. **2020 May 17**;S1083-8791(20)30286-X
61. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, **William BM**, Zain J, Dwyer MA, Sundar H, Kim YH: NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. *J Natl Compr Canc Netw* **2020 May**;18(5):522-536
62. Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, **William B**, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M: Impact of Type of Reduced-Intensity Conditioning Regimen on the Outcomes of Allogeneic Haematopoietic Cell Transplantation in Classical Hodgkin Lymphoma. *Br J Haematol*. **2020 Apr 21**. doi: 10.1111/bjh.16664. Online ahead of print.
63. Maakaron JE, Liscynsky C, Boghdadly ZE, Huang Y, Agyeman A, Brammer J, Penza S, Efebera Y, Benson D, Rosko A, **William B**, Jaglowski SM: Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look. *Biol Blood Marrow Transplant*. **2020 Apr 15**;S1083-8791(20)30212-3
64. Solomon SR, Martin AS, Zhang MJ, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LA, Brunstein C, Chhabra S, Perez MAD, Fuchs EJ, Ganguly S,

Hardy N, Hematti P, McGuirk J, Peres E, Ringden O, Rizzieri D, Romee R, Solh M, Szwajcer D, van der Poel M, Waller E, **William BM**, Eapen M: Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. *Biol Blood Marrow Transplant.* **2020 Jul 7**. S1083-8791(20)30406-7

65. Singer S, **William BM**: Use of thrombopoietin receptor agonists after hematopoietic progenitor cell transplantation. *Adv Cell Gene Ther.* 2020; 3:e102. <https://doi.org/10.1002/acg2.102> 2020
66. Jagers JL, Giri S, Klepin HD, Wildes TM, Olin RL, Artz A, Wall S, Jaglowski S, **William B**, Benson DM, Rosko AE: Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. *J Geriatr Oncol* **2020 Aug 24**;S1879-4068(20)30410- 2020
67. Kittai AS, Bond DA, **William B**, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM: Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. *Blood Adv.* **2020 Oct 13**;4(19):4648-4652 2020
68. Reneau JC, **William BM**: Autologous stem cell transplant in first remission for transformed indolent non-Hodgkin lymphoma: additional data to guide practice. *Br J Haematol.* **2020 Oct 16**. doi: 10.1111/bjh.17075. Online ahead of print 2020
69. Grana A, Gut N, Williams K, Maakaron J, Porter K, **William BM**, Vasu S, Penza S, Brammer JE, Saad A, Puto M, Jaglowski SM, Roddy J: Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk.* **2020 Oct 8**: S2152-2650(20)30557-7 doi: 10.1016/j.clml.2020.10.005. Online ahead of print. 2020
70. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, **William BM**, Zain J, Dwyer MA, Sundar H: NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. *J Natl Compr Canc Netw.* **2020 Nov 2**;18(11):1460-1467. doi: 10.6004/jnccn.2020.0053 2020
71. Rasor B, Dickerson T, Zhao Q, Elder P, Brammer JE, Larkin K, Jaglowski S, Mims A, Penza S, Vasu S, Wall SA, **William B**, Saad A, Roddy JVF, Choe H, Puto M: Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS. *Leuk Lymphoma.* 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677. Online ahead of print. 2020
72. Chung CG, **William BM**: Editorial: Cutaneous T-Cell Lymphomas. *Front Oncol.* 2021 Feb 9;11:649714 2021
73. Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, **William BM**, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y: Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation. *Cancers (Basel).* 2021 Feb 4;13(4):613 2021
74. Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, 2021

- Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, **William BM**, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D: Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. *J Immunother Cancer*. 2021 Aug;9(8):e002303
75. Jacobson CA, Chavez JC, Sehgal AR, **William BM**, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Chi H, Fung H, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: A Single-Arm, Multicenter, Phase 2 Trial. *Lancet Oncol*. 2022 Jan;23(1):91-103. 2021
76. Schaefer A, Huang Y, Kittai A, Maakaron JE, Saygin C, Brammer J, Penza S, Saad A, Jaglowski SM, **William BM**: Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience. *Cancer Manag Res*. 2021 Nov 30; 13:8901-8906 2021
77. Denlinger N, Huang Y, Braunstein Z, Sigmund A, Bajwa A, Kapoor N, Agyeman A, Fisher S, Purdin Z, Neal A, Yucebay F, Roddy J, Brammer J, **William B**, Saad A, Penza S, Voorhees T, Kittai A, de Lima M, Vasu S, Jaglowski S: ABCL-509 Healthcare Utilization and Costs in Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2022 Oct;22 Suppl 2:S381-S382 2022
78. Chavez J, Foss FM, **William B**, Brammer JE, Smith S, Prica A, Zain J, Tuscano JM, Shah H, Mehta-Shah N, Ramakrishnan Geethakumari P, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng LI, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL: Targeting the Inducible T-cell Costimulator (ICOS) in Refractory/Relapsed Peripheral T-Cell Lymphoma Follicular Variant and Angioimmunoblastic T-Cell Lymphoma. *Clin Cancer Res* Feb 24: CCR-22-2955. (Online ahead of print) 2023
79. Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, **William BM**, Cohen JB, Baiochi RA, Maddocks K, Blum KA, Alinari L. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. *Cancers (Basel)*. 2023 Feb 24;15(5):1437 2023
80. Maakaron J and **William, BM**. Age is no Barrier: CAR-T Therapy in Older Adults *Drugs and Aging* 2023 Aug;40(8):685-689 2023
81. Curran KJ, Nikiforow S, Bachier C. Hsu YM, Maloney DG, Maus MV, McCarthy PL, Porter DL, Shi PA, Shpall EJ, **William B**, Wacker K, Warkentin P, Heslop HE. Robust Quality Infrastructure is Key to Safe and Effective Delivery of Immune Effector Cells: How FACT-Finding Can Help. *Blood Advances* 2023 (July 19; Online ahead of print) 2023
82. Woost PG, **William BM**, Cooper BW, Ueda Oshima M, Otegbeye F, De Lima MJ, Wald D, Mahfouz RZ, Sauntharajah Y, Stefan T, Jacobberger JW. Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies. *Cytometry B Clin Cytom*. 2024 Jan;106(1):11-24 2024

83. Jiang J, Sigmund AM, Zhao Q, Elder P, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Wall S, Grieselhuber N, **William B**, Penza S, Benson DM, Efebera YA, Sharma N. N. Impact of chronic graft-versus-host disease on non-relapse mortality and survival. *Leuk Lymphoma*. 2024 Jun 12;:1-8. [Epub ahead of print] 2024
84. Le B, Soror N, Ismail HD, Baker M, Shetayyah SA, Chung CG, **William BM**. Narrowing of the Racial Disparities Gap in Survival of Patients With Mycosis Fungoides: A Longitudinal Analysis of the SEER Database. *Clin Lymphoma Myeloma Leuk*. 2025 Feb 25:S2152-2650(25)00075-8. Online ahead of print. 2025
85. Gupta M, Schoettler ML, Brazauskas R, Bo-Subait S, Orozco G, Battiwalla M, Buchbinder D, Hamilton BK, Savani BN, Schoemans H, Sorrow ML, Ahmed S, Badawy SM, Bhushan V, Birdsey K, Couriel D, Doherty EE, Donato M, Farag SS, Gutman J, Horwitz M, El Jurdi N, Maakaron JE, Maziarz RT, Pineiro L, Schiller G, Weisdorf DJ, **William BM**, Shaw BE, Phelan R, Porter DL, Abt PL, Levine M. Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research and Organ Procurement and Transplantation Network Study. *Transplantation*. 2025 Oct 1;109(10):1626-1638 2025
86. Gupta M, Schoettler ML, Orozco G, Brazauskas R, Bo-Subait S, Battiwalla M, Buchbinder D, Hamilton BK, Savani BN, Schoemans H, Sorrow ML, Ahmed S, Badawy SM, Bhushan V, Birdsey K, Couriel D, Doherty EE, Donato M, Farag SS, Gutman J, Horwitz M, El Jurdi N, Maakaron JE, Maziarz RT, Pineiro L, Schiller G, Weisdorf DJ, **William BM**, Shaw BE, Phelan R, Porter DL, Levine M, Abt PL. Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study. *Transplantation*. 2025 Oct 1;109(10):1611-1625 2025
87. Tuscano JM, Othman T, Frankel P, Ruel C, Poh C, Herbert S, Maverakis E, Merleev AA, Luxardi G, Abedi M, Ranganathan R, Modi D, Zain J, Budde EL, Mei M, Rosenberg AS, Hoeg RT, Costello C, Foss FM, **William BM**, Holland HK, Sharon E, Streicher H, Newman E. A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis. *Blood Adv*. 2026 Feb 24;10(4):1153-1162. 2025

Book Chapters

1. **William BM** and Vose JM (2013): T-cell lymphomas in Younes A and Coiffier B (editors): *Lymphoma Diagnosis and Treatment*. New York: Springer Publishing Company
2. Bouska A, Bagvati S, Iqbal J, **William BM**, and Chan WC (2012): Follicular lymphoma: Recent advances in Tao J and Sotomayor E (editors): *Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics*. New York: Springer Publishing Company
3. **William BM**, Hourigan CS, and deLima M (2015): Preventing Relapse post-transplant in Lazarus HM et al (editors): *Hematopoietic Transplantation: Bone Marrow, Blood and Cell Therapies*. Cambridge University Press, Cambridge, UK (in press)
4. Gerson SL, Caimi PF, **William BM**, and Creger RJ (2017): Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies in Hoffman R et al (editors): *Hematology: Basic Principles and Practice* (7th Edition). Churchill Livingstone/Elsevier
5. Hanel WG, Chung CG, Mladkova N, Weldon M, **William B**, Welliver MX (2022): Treatment of Cutaneous

Lymphomas: Topical, Systemic, and Radiation Therapies. In: Kim E, Parvathaneni U, Welliver MX (editors) Radiation Therapy for Sarcomas and Skin Cancers. Practical Guides in Radiation Oncology. Springer, Cham.

Published Abstracts and Presentations

1. **William BM**, Abdel-tawab AM, Hassan EA, Mohamed, OF (2003): Acetylator Phenotyping in patients with malignant lymphomas (BSH Abstract). British Journal of Hematology; 121(Suppl.1): 67-68
2. **William BM**, Kane KM (2003): Spindle cell carcinoma of the lung presenting with diffuse bone marrow involvement (Poster). Pennsylvania College of Internal Medicine Annual meeting
3. **William BM**, Moliterno AR, Spivak JL (2003): Transcription Factor Expression Profiling of Polycythemia Vera and Normal CD34+ Cells (ASH Abstract). Blood; 102(11): a664
4. **William BM**, Kane KM, Ottonello DG (2004): A case of bilateral leukemic ankle arthritis in an adult successfully treated with radiotherapy (Poster). Pennsylvania College of Internal Medicine Western Chapter Meeting. Awarded certificate of merit from the ACP for best poster presentation
5. **William BM**, Onadeko O (2004): Efficacy of Platelet-rich Plasmapheresis in reducing exposure to allogenic red cell transfusions in cardiac surgery patients: A meta-analysis of randomized controlled trials (SCCM Abstract). Critical Care Medicine; 32 (12supp): A163
6. **William BM**, Moliterno AR, Spivak JL (2005): Transcription Factor Expression Profiling of Polycythemia Vera and Normal CD34+ Cells. Preliminary evidence of stem cell resistance to Transforming growth factor-Beta (EHA Abstract). Haematologica; 90(s2): 258
7. **William BM**, Goodrich A, Peng C, Li S (2006): Curcumin inhibits proliferation of leukemic cells expressing P210BCR-ABL or BCR-ABL-T315I and prolongs survival of mice with B-cell acute lymphoblastic leukemia (ASH Abstract). Blood; 108(11): a535
8. **William BM**, Hohenstein M, Loberiza FR, Caponetti GC, Bociek RG, Bierman PJ, Armitage JO, Chan WC, Vose JM (2010): Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (ASH Abstract-Oral presentation). Blood; 116(21): a288
9. **William BM**, Raichlin E, Um JY, Morris MC, Miles CD, Groggel GC, Faber EA (2011): Successful Autologous Stem Cell Transplant Following a Combined Heart-Kidney Transplantation for AL Amyloidosis (BMT Tandem Meeting Abstract). Biology of Blood and Marrow Transplantation; 17(2): s155
10. **William BM**, Loberiza FR, Whalen V, Bierman PJ, Bociek RG, Vose JM, Armitage JO (2011): Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation (ASCT) for Hodgkin lymphoma (ASCO abstract). Journal of Clinical Oncology; 29(15_suppl):a8043
11. **William BM** and Rajan SK (2011): Heparin-Induced Thrombocytopenia in Liver Transplant Recipients (ASH abstract). Blood; 118(21): a4668
12. **William BM**, Allen MS, Loberiza FR, Bociek RG, Bierman PJ, Armitage JO and Vose JM (2012): Phase I/II Study of VELCADE®-BEAM (V-BEAM) and Autologous Hematopoietic stem cell transplantation (ASCT) for relapsed indolent non-Hodgkin's lymphoma (NHL), Transformed or Mantle Cell Lymphoma (MCL) (BMT Tandem Meeting Abstract). Biology of Blood and Marrow Transplantation; 18(2):S246-247
13. Bongu NR, **William BM**, Bast MA, Bociek RG, Bierman PJ, Vose JM, Armitage JO (2012): The utility

of serum lactate dehydrogenase (LDH) in the follow-up of patients with diffuse large B-cell lymphoma (DLBCL) (ASCO abstract). *Journal of Clinical Oncology*; 30(15_suppl):a8047

14. **William BM**, Kady N, Perry AM, Klinetobe K, Bociek RG, Bierman PJ, Vose JM, Armitage JO, Weisenburger DD, Busik JV (2013): Impact of bone marrow neuropathy on outcomes of autologous stem cell transplantation (ASCT) for lymphomas (BMT Tandem Meeting Abstract). *Biology of Blood and Marrow Transplantation*; 19(2):S191-192
15. Caimi PF, Sobecks R, Fu P, Cooper BW, Campagnaro EL, **William BM**, Abu-Arja R, Kolk MJ, Creger RJ, Duong HK, Hill BT, Bolwell BJ, Kalaycio M, de Lima M, Lazarus HM (2013): Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT (ASH abstract). *Blood*; 122(21): a2117
16. Caimi PF, Gupta K, Stefan T, Cooper B, **William BM**, Campagnaro EL, Creger RJ, Kane D, Gerson SL, Lazarus HM, de Lima M, Wald DN (2014): All-Trans-Retinoic Acid (ATRA) Combined with Lithium As Treatment of Relapsed Non-Plasmacytic AML: Therapeutic Targeting Inhibition of the Glycogen Synthase Kinase 3-Beta (GSK3) Enzyme (ASH abstract). *Blood*; 124: a5299
17. Ravi G, Cooper B, Campagnaro EL, **William BM**, Creger RJ, Gerson SL, De Lima M, Lazarus HM, Caimi PF (2014): Increased Risk of Venous Thromboembolism in Primary Central Nervous System Lymphoma Patients Undergoing Therapy (ASH abstract). *Blood*; 124: a5431
18. Fung H, Sloan AE, Reese J, **William BM**, Lingas K, Rogers LR, Embree H, Lazarus HM, Kane D, Dropulic B, Gerson SL (2014): Viral Insertion Safety in Patients with Glioblastoma Who Received a Novel Lentiviral MGMT-P140K Gene Therapy to Protect Bone Marrow from Chemotherapy: No Dominant Clonal Evolution Observed with Chemo-Selection (ASH abstract). *Blood*; 124: a4801
19. Caimi PF, Cooper BW, **William BM**, Campagnaro EL, Creger RJ, Afable M, Xu Y, Pink J, Dowlati A, Lazarus HM, de Lima M, Gerson SL (2014): Phase I Trial of the Base – Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies (ASH abstract). *Blood*; 124: a4688
20. Afable M, Caimi PF, Hosing C, de Lima M, Khouri IF, **William BM**, Nieto Y, Cooper BW, Anderlini P, Campagnaro EL, Gerson SL, Lazarus HM, Champlin RE, Popat UR (2014): Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT) (ASH abstract). *Blood*; 124: a3854
21. **William BM**, Moreton S, Reese J, Fu P, Busik JV, de Lima M, Wald DN (2014): Fingolimod Expands Human Umbilical Cord Blood Cells (UCB) in Vitro and Improves Engraftment Rate of Human UCB in Sublethally Irradiated NOD SCID Gamma (NSG) Mice (ASH abstract). *Blood*; 124: a2413
22. **William BM**, Feng D, An W, Nadeau S, Mohapatra B, Storck M, Band H (2014): Fasudil, a Rho-Associated Protein Kinase (ROCK) Inhibitor, Decreases Disease Burden in a Cbl/Cbl-b Deficiency-Driven Murine Model for Myeloproliferative Disorders (ASH abstract). *Blood*; 124: a4569
23. **William BM**, de Lima M, Oran B, Champlin R, Papadopoulos EB, Giralt S, Scott BL, Hetzer J, Wang X, Laille E, Skikne BS, Craddock C (2014): CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) (ASH abstract). *Blood*; 124: a990
24. Yao DC, Caimi P, Lazarus HM, Cooper B, Creger C, **William BM**, Kolk M, de Lima M (2015): ATG Use and Post-Allogeneic Transplant Viral EBV, CMV, HHV-6 and HHV-8 Reactivation. *Biology of Blood and Marrow Transplantation*; 21(2), S320-S321
25. **William BM**, Woost P, Mahfouz R, Brister L, Caimi P, Campagnaro E, Cooper B, Lazarus HM, Sauntharajah Y, de Lima M, Komanduri KV, Jacobberger J (2015): DNA Methyltransferase-1

(DNMT1): A Flow Cytometric Pharmacodynamic Assay for Azacitidine Hypomethylating Therapy after Allogeneic Hematopoietic Stem Cell Transplantation (BMT Tandem Meeting Abstract). *Biology of Blood and Marrow Transplantation*; 21(2), S318-319

26. Oyetakin-White P, Vyas R, **William BM**, Meyerson H, Li J, Ciarlini P, Cooper K, Kord H (2015): Blastic Plasmacytoid Dendritic Cell Neoplasm associated with myelodysplasia. Annual Meeting of the American Academy of Dermatology; a1997.
27. de Souza A, Njoroge J, Al-Kindi S, Qattan M, Hoit BD, Liner A, Wilson J, **William BM**, De Lima MJ, Oliveira G (2015): Efficacy of preemptive betablockers for prevention of cardiotoxicity in patients undergoing hematopoietic stem cell transplantation (ASCO abstract). *Journal of Clinical Oncology*; 33 suppl Ae18012
28. Ueda M, Gupta D, Caimi PF, Creger R, Little J, **William BM**, Lazarus HM, de Lima M, Cooper BW (2015): Hospitalization rates in elderly, newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients treated with azacitidine (ASCO abstract). *Journal of Clinical Oncology*; 33 suppl Ae1840
29. Starr AG, Fu P, Caimi PF, Campagnaro E, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Meyerson H, Jagadeesh D, Smith MR, Dean RM, Pohlman ML, Hill BT, **William BM** (2015): Outcomes and prognostic factors in marginal zone lymphoma: Case Comprehensive Cancer Center cumulative experience of 358 cases (ASCO Abstract). *Journal of Clinical Oncology*; 33 suppl A8854
30. **William BM**, Askew D, Vatsayan A, Eid S, Cooper BW, De Lima M, Huang A (2016): Fingolimod (FTY720), in Clinically-Safe Doses, Ameliorates Graft-Versus-Host Disease (GVHD) in Murine Model of Haploidentical Hematopoietic Stem Cell Transplantation (BMT Tandem meeting Abstract). *Biology of Blood and Marrow Transplantation*; 22(3), S416–S417
31. De Lima M, Oran B, Papadopoulos EB, Scott BL, **William BM**, Giralt S, Champlin R, Hetzer J, Tosolini A, Laille E, Skikne BS, Craddock C (2016): CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (BMT Tandem meeting Abstract). *Biology of Blood and Marrow Transplantation*; 22(3), S312–S313
32. Silva C, Whitton T, **William BM**, Gerson SL, Cooper BW, Lazarus HM, De Lima M, Caimi PF (2016): Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia (BMT Tandem meeting Abstract). *Biology of Blood and Marrow Transplantation*; 22(3), S210–S211
33. Singer S, Efebera YA, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Jaglowski S, **William BM**, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Majhail N, Devine SM, Dean R (2016): A Two-Center Retrospective Comparison of Beam vs. Bucyvp16 Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma. (EHA Meeting Abstract). Clinical Final Abstract Identifier: E1513
34. Richardson DR, Huang Y, Elder P, Newlin J, Kirkendall C, Devine SM, Andritsos LA, Benson DM, Blum W, Efebera YA, Hofmeister CC, Jaglowski S, Klisovic RB, McGinty HL, Penza S, Vasu S, **William BM**, Rosko AE (2016): Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation (ASH abstract), *Blood* 128:1241
35. **William BM**, Wang T, Haagenson MD, de Lima MJ, Fernandez-Vina MA, Spellman S, Lee SJ, Hill BT (2016): Impact of Human Leukocyte Antigen (HLA) Alleles on Outcomes of Allogeneic Transplantation (Allo-HCT) for B-Cell Non-Hodgkin Lymphomas (B-NHL); A CIBMTR Analysis (ASH Abstract). *Blood* 128:3491
36. Bagot M, Porcu P, Ram-Wolff C, Khodadoust M, **William B**, Battistella M, Marie-Cardine A, Mathieu

- S, Vermeer M, Whittaker S, Duvic M, Bensussan A, Paturel C, Bonnafous C, Thonnart N, Widemann A, Bonin C, Sicard H, Paiva C, Pilz K, Kim YH (2017): Phase I of IPH4102, Anti-KIR3DL2 Mab, in relapsed/refractory Cutaneous T-cell Lymphomas (CTCL): dose-escalation safety, biomarker and clinical activity results (International Conference on Malignant Lymphoma; ICML Lugano Abstract). *Hematological Oncology*; 35(Suppl 1): 48-49
37. Waller A, Lundberg J, Porter K, Hwang S, Hastings J, Haverkos B, Brammer J, Fabbro S, **William BM**, Dotson E, Porcu P (2017): Gemcitabine plus liposomal doxorubicin for relapsed refractory T-cell lymphomas (International Conference on Malignant Lymphoma; ICML Lugano Abstract). *Hematological Oncology*; 35(Suppl 1): 2409-
 38. Querfeld C, Foss FM, Porcu P, Kim YH, Pacheco T, Haverkos B, Halwani AS, DeSimone J, **William B**, Pinter-Brown L, Seto A (2017): Phase 1 trial evaluating MRG-106, microRNA-155 inhibitor, administered by intratumoral, subcutaneous, or intravenous delivery in patients with cutaneous t-cell lymphoma (CTCL) (International Conference on Malignant Lymphoma; ICML Lugano Abstract). *Hematological Oncology*; 35(Suppl 2): 275-6.
 39. Denlinger N, Hwang S, Kline D, McLaughlin E, Fabbro S, Brammer JE, Mishra A, **William BM**, Porcu P. Frequency, cell lineage, and clinical correlates of lymphopenia in untreated T-cell lymphomas (ASCO Abstract). *Journal of Clinical Oncology*;35(15_suppl):e19023-e
 40. Foss FM, Querfeld C, Porcu P, Kim YH, Pacheco T, Halwani AS, DeSimone J, **William BM**, Seto AG, Ruckman J, Landry ML, Jackson AL, Pestano LA, Dickinson BA, Sanseverino M, Rodman DM, Rubin P, Gordon GS, Marshall WS (ASCO Abstract): Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL). *Journal of Clinical Oncology*;35(15_suppl):7564-.
 41. Bagot M, Porcu P, Ram-Wolff C, Khodadoust M, **William B**, Battistella M, Marie-Cardine A, Mathieu S, Vermeer M, Whittaker S, Duvic M, Bensussan A, Paturel C, Bonnafous C, Bonin C, Moriette F, Lagache L, Sicard H, Paiva C, Pilz K, Kim YH (2017): IPH4102, The First-In-Class anti-KIR3DL2 Mab, Is Safe And Clinically Active In Advanced Cutaneous T-Cell Lymphoma (CTCL) Patients: Results From The Dose-Escalation Part Of The IPH4102-101 Phase I Study (EORTC-CTLF Meeting abstract) European Organisation for Research and Treatment of Cancer/Cutaneous Lymphoma Foundation Meeting (London, UK)
 42. Battistella M, Marie-Cardine A, Paturel C, Bonnafous C, Thonnart N, Khodadoust M, Widemann A, Bagot M, Kim YH, Porcu P, Bagot M, Porcu P, Ram-Wolff C, , **William B**, Mathieu S, Mathieu S, Vermeer M, Whittaker S, Bensussan A, Dujardin A, Paiva C, Pilz K, Sicard H (2017): Biomarkers of pharmacological and clinical activity of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in A Phase I Study In Patients With Relapsed/Refractory CTCL (EORTC-CTLF Meeting abstract) European Organisation for Research and Treatment of Cancer/Cutaneous Lymphoma Foundation Meeting (London, UK)
 43. Querfeld C, Foss FM, Pinter-Brown LC, Porcu P, **William BM**, Pacheco T, Haverkos BM, Kim YH, Guitart J, Halwani AS, DeSimone J, Seto AG, Pestano LA, Jackson AL, Williams PJ, Dickinson BA, Ruckman J, Gordon G, Rubin P, Marshall BS (2017): Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients (ASH Abstract). *Blood*. 2017;130(Suppl 1):820-.
 44. Vaughn JL, Zhao Q, Ranganathan P, Elder P, **William BM**, Puto M, Roddy J, Klisovic R, Blum W, Benson DM, Jaglowski SM, Mims AS, Brammer JE, Bhatnagar B, Efebera YA, Hofmeister CC, Andritsos LA, Penza S, Walker AR, Devine SM, Cataland SR, Vasu S (2017): Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab (ASH Abstract). *Blood*;130(Suppl 1):1932-.
 45. Mundy-Bosse BL, Denlinger N, Huang S, Chen L, Mao H, Kline D, McLaughlin E, Youssef Y, Young K, Lozanski G, Freud AG, Porcu P, **William BM**, Caligiuri MA, Mishra A (2017): Enhanced

Spontaneous Anti-Tumor Cytotoxicity of Natural Killer Cells in Cutaneous T-Cell Lymphoma Patients (ASH Abstract). Blood;130 (Suppl 1):2753-.

46. de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, **William BM**, Hetzer J, Hubbell B, Skikne BS, Craddock C (2017): Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) (ASH Abstract). Blood; 130(Suppl 1):4512-
47. Wall SA, Zhao Q, Ranganathan P, Elder P, **William BM**, Puto M, Roddy J, Klisovic RB, Blum W, Benson DM, Jaglowski S, Mims AS, Brammer JE, Efebera YA, Hofmeister CC, Andritsos L, Penza S, Walker AR, Devine SM, Cataland SR, Vasu S (2017): Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity (ASH Abstract). Blood;130(Suppl 1):4483-.
48. El Jurdi NH, Ueda M, Woost P, Lazarus HM, Caimi P, Cooper BW, Creger R, Little JA, Baer L, Brister L, Malek E, Metheny L, Otegbeye F, Tomlinson BK, **William BM**, Jacobberger J, De Lima M (2017): Pilot Use of a Novel DNA Methyltransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation (ASH Abstract). Blood, 130 (Suppl 1) 5503
49. Collins J, Chung C, **William BM** (2018): Primary Cutaneous Pleomorphic Small-Medium CD4+ T-Cell Lymphoma: A Case Series (TCF Poster). International T-cell Lymphoma Forum, La Jolla, CA
50. Foss FM, Querfeld C, Kim YH, Pinter-Brown LC, **William BM**, Porcu P, Pacheco T, Haverkos B, DeSimone J, Guitart J, Halwani AS, Eradat HA, Huen A, Seto AG, Pestano LA, Gordon GS, Escolar D, Rubin P, Marshall WS, and Williams J (2018): Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL (ASCO Abstract). Journal of Clinical Oncology 36:15_suppl, 2511-2511
51. Bagot M, Porcu P, **William B**, Vermeer M, Whittaker S, Ram Wolff C, Khodadoust m, Battistella M, Paiva C, Sicard H, Azim H, Kim Y (2018): IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study (EORTC-CTLF Meeting abstract) European Organisation for Research and Treatment of Cancer/Cutaneous Lymphoma Foundation Meeting. European Journal of Cancer, Volume 101, S29
52. Johnson W, Kohnken R, McNeil B, Wen J, McConnell K, **William B**, Burrows F, Porcu, Mishra A (2018): Pre-Clinical Activity of Tipifarnib in Cutaneous T-Cell Lymphoma (Society of Hematologic Oncology 2018 Annual Meeting). Clinical Lymphoma, Myeloma and Leukemia, Volume 18, S283 - S284
53. **William BM**, Brillhart K, Afable M, Bakalarz K, Cooper B, Lazarus HM, Gerson SL, Creger R, Nagabhushanam K, Grote J, Fu P, Kunati S, Yang S, Xu Y, Woost P, Jacobberger J, de Lima M, and Caimi P (2018): A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (ASH abstract). Blood;132:1875
54. Querfeld C, Foss FM, Kim YH, Pinter-Brown L, **William BM**, Porcu P, Pacheco T, Haverkos BM, DeSimone J, Guitart J, Halwani AS, Eradat HA, Huen A, Schroeder K, Pestano LA, Williams PJ, Cheronis I, Gordon GS, Escolar D, Rubin P, Marshall WS (2018): Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma (ASH abstract). Blood;132:2903
55. Saygin C, Vaughn JL, Coleman J, Puto M, Roddy J, Penza S, Brammer JE, Efebera Y, Benson DM, Vasu S, Walker AR, Mims AS, Bhatnagar B, Blaser B, Chaudhry M, Choe H, Larkin K, Long M, Rosko A, Grieselhuber N, Wall S, Devine S, Jaglowski S, **William BM** (2018): Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor

Transplantation (ASH Abstract). Blood;132:3357

56. Maddocks KJ, Awan FT, Huang Y, Ayyappan S, Baiocchi RA, Epperla N, Jaglowski S, **William BM**, Blum KA, Christian BA (2018): Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma (ASH Abstract). Blood;132:4185
57. Bagot M, Porcu P, **William BM**, Battistella M, Vermeer M, Whittaker S, Ram-Wolff C, Khodadoust MS, Sicard H, Azim HA, Kim YH (2018): IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial (ASH Abstract). Blood;132 (Suppl 1) 68
58. Querfeld C, Foss F, Pinter-Brown L, **William B**, Kim Y, Guitart J, et al. Results from Phase 1 Trial of Cobomarsen, an inhibitor of miR-155, in mycosis fungoides (TCF Poster). International T-cell Lymphoma Forum, La Jolla, CA
59. Abbasi A, Chung C, **William BM** (2019): Tumor flare reaction in a patient with cutaneous T-cell lymphoma treated with brentuximab and lenalidomide associated with durable disease control (TCF Poster). International T-cell Lymphoma Forum, La Jolla, CA
60. **William BM**, Abbasi A, Giali R, Huang Y, Grantier C, Hoffman C, Brammer J, and Chung C (2019): Brentuximab vedotin and lenalidomide in relapsed and refractory cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas: Preliminary results of a phase II trial (TCF Poster). International T-cell Lymphoma Forum, La Jolla, CA
61. Schaefer A, Saygin C, Maakaron J, Hoelscher T, Purdin Z, Robinson J, Lamprecht M, Penza S, Brammer JE, Efebera YA, Benson DM, Vasu S, Mims A, Blaser B, Choe H, Larkin K, Long M, Rosko A, Grieselhuber N, Wall S, Jaglowski S, **William BM** (2019): Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion; Patterns and Outcomes (TCT Meeting Abstract). Biology of Blood and Marrow Transplantation, Volume 25, Issue 3 , S171
62. Maakaron J, Liscynesky C, El Boghdadly Z, Penza S, Brammer JE, Efebera Y, Benson D, Vasu S, Mims A, Blaser B, Choe H, Larkin K, Long M, Rosko A, Grieselhuber N, Wall S, **William BM**, Jaglowski S (2019): Levofloxacin Prophylaxis for Autologous Stem Cell Transplant: A Second Look (TCT Meeting Abstract). Biology of Blood and Marrow Transplantation, Volume 25, Issue 3 , S148
63. Grantier C, Gung C, **William BM**, Porcu P (2019): Quality of Life in Cutaneous T-Cell Lymphoma Subjects Treated with Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from the Phase 3 MAVORIC Trial (ONS Abstract). Oncology Nursing Society's Annual Conference, Anaheim, CA.
64. Abbasi A, Chung C, **William BM** (2019): Case Series: The Treatment of Hypereosinophilic Disorder-Lymphocytic Variant with Romidepsin (WCD Poster). World Congress of Dermatology, Milan, Italy
65. Maakaron J, Zhao Q, Puto M, Von Derau R, Robinson J, Brammer J, Penza S, Baiocchi R, Christian B, Maddocks K, Saad A, Wall S, Benson D, Efebera Y, Rosko A, Ayyappan S, Grieselhuber N, Vasu S, Larkin K, Epperla N, Devarakonda S, Choe H, Chaudhry M, Blaser B, Blachly J, Bhatnagar B, Alinari L, Mims A, Jaglowski S, **William BM** (2019): Phase I dose-escalation study of venetoclax plus BEAM followed by autologous stem cell transplant (ASCT) for chemoresistant, relapsed/refractory, or high-risk non-Nodgkin's lymphoma (NHL); preliminary results (ICML Lugano Abstract).] Hematological Oncology; Vol. 37 Suppl. 2 June 2019 A503
66. **William BM**, Abbasi A, Huang Y, Larbi R, Giali R, Yang L, Brammer J, Grantier C, Hoffman C, Ayyappan S, Baiocchi R, Epperla N, Christian B, Alinari L, Maddocks K, and Chung C (2019): Brentuximab vedotin and lenalidomide in relapsed and refractory cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas: Preliminary results of a phase II trial (ICML Lugano Abstract).] Hematological Oncology; Vol. 37 Suppl. 2 June 2019 A439

67. **William BM**, Huang Y, Brammer J, Chung C (2019): A Phase II Trial of Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; Preliminary Results (SOHO abstract – oral presentation). Clinical Lymphoma, Myeloma and Leukemia, 19, S359-S360
68. Maakaron J, Huang Y, Brammer J, Chung C, **William BM** (2019). A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas (EORTC CTLF Meeting abstract – oral presentation). European Journal of Cancer, 119, S28.
69. Poh C, Frankel P, Ruel C, Abedi M, Schwab E, Costello C, Zain J, Budde L, **William BM**, Foss F, Jonas B, Rosenberg AS, Newman E, Tuscano J (2019): Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis (ASH Abstract). Blood;134 (Suppl 1) a760
70. Querfeld C, **William BM**, Brammer JE, Sokol L, Tagaya Y, Frohna P, Azimi N, Zain JM (2019): Bnz-1, a Selective γ -Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial (ASH Abstract). Blood;134 (Suppl 1) a1557
71. Maakaron J, Zhao Q, Puto M, Verfurth Q, Penza S, Brammer JE, Efebera YA, Rosko AE, Saad A, Jaglowski S, **William BM** (2019): Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) (ASH Abstract). Blood;134 (Suppl 1) a2024
72. **William BM**, Huang Y, Johnson A Brammer JE, Reneau JC, Maakaron J, MD4, Larbi R, Grantier C, Hoffman C, Ayyappan S, Baiocchi RA, Epperla N, Christian BA, Alinari L, Maddocks K, Chung C (2019): Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial (ASH Abstract). Blood;134 (Suppl 1) a2853
73. David KA, Pulitzer M, Guitart J, Martinez-Escala ME, Geller S, Wang Y, Bennani N, Ristow K, Landsburg DJ, Winchell N, Haun P, Allen P, **William BM**, Denlinger N, Mehta-Shah N, Wilcox RA, Hristov A, Feldman TA, Weller A, Evens AM, Horwitz SM (2019): Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy (ASH Abstract). Blood;134 (Suppl 1) a4028
74. Christian BA, MD1, Huang Y, Ayyappan S, Baiocchi RA, MD, Brammer JE, Epperla N, MD, Jaglowski S, **William BM**, Awan FT, Maddocks KJ, Blum KA (2019): Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma (ASH Abstract). Blood;134 (Suppl 1) a4082
75. Bond DA, Yildiz V, Wei L, Alinari L, **William BM**, Brammer JE, Christian BA, MD6, Blum KA, Maddocks KJ (2019): A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma (ASH Abstract). Blood;134 (Suppl 1) a4091
76. Stephens DM, Huang Y, Agyeman A, Ruppert AS, Hu B, Turner N, Vadeboncoeur R, Rogers KA, Bhat SA, MD7, **William BM**, Jaglowski S, Lockman H, Glenn M, Lapalombella R, Byrd JC, Woyach J, MD (2019): Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study (ASH Abstract). Blood;134 (Suppl 1) a4310
77. Sharma N, Ni, B, Zhao Q, Elder P, Benson BM, Rosko AE, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims AS, Choe HK, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad S, Penza S, Efebera YA (2019): Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation (ASH Abstract). Blood;134 (Suppl 1) a4549

78. **William B**, Johnson A, Huang Y, Reneau J, Brammer J, Chung C. Brentuximab Vedotin (Bv) And Lenalidomide (Len) In Relapsed/Refractory (R/R) Cutaneous (CTCL) And Peripheral (PTCL) T-Cell Lymphomas; Interim Results Of A Phase II Trial. 4th World Congress Of Cutaneous Lymphomas Oral Presentation. Barcelona, Feb 2020.
79. Johnson A, Ren R, **William B**, Chung C. Robust Graft-Versus-Lymphoma (GvL) Response Mimicking Cutaneous Relapse Of T-Cell Lymphoma Internal Medicine, The Ohio State University, Columbus, United States; 2pathology, The Ohio State University, Columbus, United State 4th World Congress Of Cutaneous Lymphomas Oral Presentation. Barcelona, **Feb 2020**
80. Johnson A, Ren R, **William B**, Chung C. Paradoxical Response Of Cutaneous T-Cell Lymphoma In A Patient With Concomitant Angioimmunoblastic T-Cell Lymphoma. 4th World Congress of Cutaneous Lymphomas Oral presentation. Barcelona, **Feb 2020**
81. **William B**, Johnson A, Huang Y, Reneau J, Brammer J, Chung C. Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed/Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; interim results. (Poster) T-Cell Lymphoma Forum. **February 2020**
82. Sharma N, Zhao Q, Elder P, Benson D, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William B**, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y. Relationship of Tacrolimus Concentration and Incidence of Acute Graft-versus-Host Disease after Allogenic Stem Cell Transplantation. 2020 Transplantation and Cellular Therapy, Abstract Orlando Florida, **Feb 2020**
83. Brammer J, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Smith S, Vasu S, Haddad D, Gumina R, **William B**, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Binkley P, Jaglowski S, Addison D. Cardiovascular Toxicity and Clinical Outcomes Following Chimeric Antigen Receptor T_{cell} Infusion (CAR T) for Lymphoid Malignancies. 2020 Transplantation and Cellular Therapy, Abstract Orlando Florida, **Feb 2020**
84. Denlinger N, Braunstein Z, Agyeman A, Purdin Z, Neal A, Yucebay F, Roddy J, Brammer J, Saad A, Penza S, **William B**, Vasu S, Huang Y, Jaglowski S. CAR T T-Cell Therapy: Clinical Outcomes, Patient Selection and Financial Metrics with Tisagenlecleucel and Axicabtagene Ciloeucel, a Single Center Experience. 2020 Transplantation and Cellular Therapy, Abstract Orlando Florida, **Feb 2020**
85. Ozga M, Schaefer A, Huang Y, Parekh H, Penza S, Brammer J, Efebera Y, Benson D, Vasu S, Mims A, Blaser B, Choe H, Larkin K, Grieselhuber N, Wall S, Lozanski G, Jaglowski S; Saad A, **William B**. Predictors of Relapse after Haploidentical Hematopoietic Progenitor Cell Transplantation (Haplo-HCT); A Single-Institute Experience. 2020 Transplantation and Cellular Therapy, Abstract Orlando Florida, **Feb 2020**.
86. Rasor B, Dickerson T, Zhao Q, Brammer J, Larkin K, Jaglowski S, Mims A, Penza S, Vasu S, Wall S, **William B**, Saad A, Roddy J, Choe H, Puto M. Comparison of Fixed Dose Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Transplant for AML/MDS. 2020 Transplantation and Cellular Therapy, Abstract Orlando Florida, **Feb 2020**.
87. Collins JG, Chung CG, **William B**. Case Report: Atypical Ulceronecrotic Lymphomatoid Papulosis Treated Successfully with Brentuximab Vedotin. 2020 Spring Meeting of the American Osteopathic College of Dermatology, **Feb 2020**
88. Jacobson CA, Chavez JC, Sehgal AR, **William BM**, Munoz J, Salles GA, Casulo C, Munshi PN, Maloney DG, De Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HC, Plaks V, Yang Y, Lee J, Avanzi MP, Neelapu SS (2020): Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloeucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). 2020 ASCO Annual Meeting, **May 2020**

89. Jacobson CA, Chavez JC, Sehgal AR, **William BM**, Munoz J, Salles GA, Casulo C, Munshi PN, Maloney DG, De Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HC, Plaks V, Yang Y, Lee J, Avanzi MP, Neelapu SS (2020): Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). 2020 European Hematology Association Meeting, June 2020
90. Jacobson CA, Chavez JC, Sehgal AR, **William BM**, Munoz J, Salles GA, Casulo C, Munshi PN, Maloney DG, De Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HC, Plaks V, Yang Y, Lee J, Avanzi MP, Neelapu SS (2020): Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). 2020 Society of Hematological Oncology Annual Meeting, **September 2020**
91. Mehta-Shah N, Kommalapati A, Teja S, Cashen AF, Dahi PB, Sauter CS, Moskowitz AJ, Jacobsen ED, **William BM**, Ozga M, Barta SK, Loren AW, Bair S, Allen PB, Sulaiman S, Song K, Alzahrani M, Ruan J, MD, van Besien K, Seshadri M, McKinney M, Beaven AW, Haverkos B, Starr A, Alpdogan O, Porcu P, Foss FM, Tao Y, Horwitz SM (2020): Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis. 2020 American Society of Hematology Annual Meeting. A41. **December 2020**
92. Querfeld Q, **William BM**, Sokol L, Akilov O, Poligone B, Zain J, Tagaya Y, Azimi N (2020): Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial. 2020 American Society of Hematology Annual Meeting. A43. **December 2020**
93. Jacobson CA, Chavez JC, Sehgal AR, **William BM**, Munoz J, Salles GA, Munshi PN, Casulo C, Maloney DG, De Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HC, Rosenblatt JD, Rossi JM, Goyal L, Plaks V, Yang Y, Lee J, Godfrey W, Vezan R, Avanzi MP, Neelapu SS (2020): Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). 2020 American Society of Hematology Annual Meeting. A700. **December 2020**
94. Chavez JC, Foss FM, **William BM**, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Glenn M, Mehta-Shah N, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Carlesso G, Moscow J, Lillian L (2020): A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930). 2020 American Society of Hematology Annual Meeting. A1151. **December 2020**
95. Soror NN, Keiter A, Zhao Q, Roddy J, Penza S, Brammer JE, Efebera YA, Benson DM, Vasu S, Mims AS, Blaser BW, Choe H, Larkin K, Grieselhuber N, Wall SA, Saad A, Rosko A, Elder P, Chaudhry M, Bumma N, Khan A, Devarakonda S, Jaglowski S, **William BM** (2020): Survival Implications of Opioid Use after Blood and Marrow Transplantation. 2020 American Society of Hematology Annual Meeting. A1499. **December 2020**
96. Chavez JC, Jacobson CA, Sehgal AR, Neelapu SS, Maloney DG, Salles G, **William BM**, Yang Y, Goyal L, Chou J, Plaks V, Avanzi, MP (2020): Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5. 2020 American Society of Hematology Annual Meeting. A2036. **December 2020**
97. Hanel W, Christian BA, Maddocks KJ, Narendranath N, **William BM**, Jaglowski S, Bond DA, Sawalha Y, Reneau JC, Brammer JE, Baiocchi R, Blum KA, Alinari L (2020): A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. 2020 American Society of Hematology Annual Meeting. A2077. **December 2020**
98. Sigmund AM, Jiang J, Zhao Q, Elder P, Benson DM, Rosko A, Chaudhry M, MD1, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims AS, Choe H, Larkin K, Brammer JE,

- Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N (2020): Improvement in Survival of AML and MDS Patients Following Allogeneic Transplant: A Long-Term Institutional Experience. 2020 American Society of Hematology Annual Meeting. A2427. **December 2020**
99. Jiang J, Zhao Q, Sigmund AM, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims AS, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N (2020): Impact of Chronic Graft-Versus-Host Disease on Non-Relapse Mortality. 2020 American Society of Hematology Annual Meeting. A2441. **December 2020**
100. Jiang J, Sigmund AM, Zhao Q, , Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims AS, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N (2020): Trend in Survival in Patients Undergoing Allogeneic Stem Cell Transplantation: An Institutional Experience. 2020 American Society of Hematology Annual Meeting. A3360. **December 2020**
101. Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims AS, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N (2020): Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant. 2020 American Society of Hematology Annual Meeting. A3362. **December 2020**
102. Ali A, Hosing C, Puto M, **William BM**, Buls S, Campbell Y, Campbell A, Nakkula RJ, Trikha P, Lee DA, Brammer JE. Maintenance Romidepsin (Rom) after Allogeneic Stem Cell Transplantation (Allo-SCT) in Aggressive T-Cell Malignancies Induces Long-Term Remissions and Enhances NK-Cell Cytotoxicity. Transplantation and Cellular Therapy. 2021;27(3):S417-S8. **March 2021**
103. Chavez JC, Jacobson CA, Sehgal AR, Neelapu SS, Maloney DG, Salles G, **William BM**, Yang Y, Goyal L, Chou J, Plaks V, Avanzi MP. Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) in Zuma-5. Transplantation and Cellular Therapy. 2021;27(3):S43. **March 2021**
104. Jacobson CA, Chavez JC, Sehgal AR, **William BM**, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung H, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Lee J, Godfrey W, Vezan R, Avanzi MP, Neelapu SS. Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Transplantation and Cellular Therapy. 2021;27(3):S67-S8. **March 2021**
105. Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims A, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience. Transplantation and Cellular Therapy. 2021;27(3):S151. **March 2021**
106. Jiang J, Zhao Q, Sigmund AM, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims A, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Impact of Chronic Graft-Versus-Host Disease on Non-Relapse Mortality and Survival. Transplantation and Cellular Therapy. 2021;27(3):S283-S4. **March 2021**
107. Maakaron J, Zhao Q, Balakrishna J, Puto M, Penza S, Brammer JE, Reneau JC, Christian B, Maddocks K, Efebera Y, Rosko A, Saad A, Jaglowski S, **William BM**. Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Adding Steam to ASCT. Transplantation and Cellular Therapy. 2021;27(3):S402-S3. **March 2021**

108. Sharma N, Jiang J, Zhao Q, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims A, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Sigmund AM, Efebera YA. Impact of Bone Marrow Versus Peripheral Blood on Outcomes in Haploidentical Transplantation. Transplantation and Cellular Therapy. 2021;27(3):S246-S7. **March 2021**
109. Sigmund AM, Jiang J, Zhao Q, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims A, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Outcomes in Allogeneic Transplant Based on Race and Geographic Location of Residence. Transplantation and Cellular Therapy. 2021;27(3):S311-S2. **March 2021**
110. Sigmund AM, Jiang J, Zhao Q, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, **William BM**, Mims A, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Trends in Survival of AML and MDS Patients Following Allogeneic Transplant. Transplantation and Cellular Therapy. 2021;27(3):S154-S5. **March 2021**
111. Soror N, Keiter A, Zhao Q, Elder P, Puto M, Penza S, Brammer JE, Efebera YA, Benson DM, Vasu S, Mims A, Blaser B, Choe H, Larkin K, Grieselhuber N, Wall SA, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Saad A, Jaglowski S, **William BM**. Impact of Opioid Use after Blood and Marrow Transplantation (BMT): A Single-Center Analysis. Transplantation and Cellular Therapy. 2021;27(3):S380-S3. **March 2021**
112. Wall SA, Huang Y, Keiter A, Kloock C, Yuhasz N, Funderburg A, Presley C, Folefac E, Vasu S, Jaglowski S, Saad A, Choe H, **William BM**, Efebera YA, Brammer JE, Bumma N, Devarakonda S, Khan A, Choe H, William BM, Efebera YA, Brammer JE, Bumma N, Devarakonda S, Khan A, Larkin K, Penza S, Benson DM, Rosko A. Geriatric Assessment with Management Highlights Importance of Nutrition in Older Adult Transplant Recipients. Transplantation and Cellular Therapy. 2021;27(3):S438-S9. **March 2021**
113. Chavez JC, Jacobson CA, Sehgal AR, Neelapu SS, Maloney DG, Salles G, **William BM**, Yang Y, Goyal L, Chou J, Plaks V, Avanzi MP. Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) in Zuma-5. European Society for Blood and Marrow Transplantation – 47th Annual Meeting. 2021;27(3):S43. **March 2021**
114. Jacobson CA, Chavez JC, Sehgal AR, **William BM**, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung H, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Lee J, Godfrey W, Vezan R, Avanzi MP, Neelapu SS. Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). European Society for Blood and Marrow Transplantation – 47th Annual Meeting. **March 2021**
115. Jacobson CA, Chavez JC, Sehgal AR, **William BM**, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung H, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Lee J, Godfrey W, Vezan R, Avanzi MP, Neelapu SS. Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Japan Society for Hematopoietic Cell Transplantation - 43rd Annual Meeting. **March 2021**
116. Jacobson CA, Chavez JC, Sehgal A, **William BM**, Munoz J, Salles GA, Casulo C, Munshi PN, Maloney DG, De Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Hang Fung HC, Plaks V, Yang Y, Lee J, Avanzi MP, Neelapu SS. Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24). ASCO Annual Meeting. **June 2021**

- 117.** Chavez JC, Jacobson CA, Sehgal A, Neelapu SS, Maloney DG, Salles GA, **William BM**, Yang Y, Goyal L, Chou J, Plaks V, Avanzi MP. Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5. ASCO Annual Meeting. **June 2021**
- 118.** **William BM**, Campbell AR, Watts M, O'Donnell L, Reneau J, Vasu S, Lee D. Mogamulizumab exhibits synergistic activity in combination with allogeneic, IL21-expanded, natural killer (NK) cells against T-cell lymphoma. 13th Annual T-cell Lymphoma Forum. **July 2021**
- 119.** **William BM**, Campbell AR, Watts M, O'Donnell L, Reneau J, Vasu S, Lee D. Mogamulizumab exhibits synergistic activity in combination with allogeneic, IL21-expanded, natural killer (NK) cells against T-cell lymphoma. 6th ESH Translational Research E-Conference on Lymphoid Malignancies. **October 2021**
- 120.** Hosing C, Braunstein Z, Ali AM, Valdez BC, Andersson BS, Popat UR, Vasu S, Larkin K, Penza S, Choe H, Saad A, de Lima MJ, Wei L, McLaughlin E, Nakkula R, Campbell A, Trikha P, Puto M, **William BM**, Champlin RE, Lee DA, Brammer JE; Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial. Blood 2021; 138 (Supplement 1): 553. American Society of Hematology Annual Meeting **December 2021**
- 121.** Maakaron J, Zhao Q, Balakrishna JP, Puto M, Ferguson W, Penza S, Brammer JE, Maddocks KJ, Efebera YA, Saad A, Jaglowski S, **William BM**; Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL). Blood 2021; 138 (Supplement 1): 656. American Society of Hematology Annual Meeting **December 2021** **(Oral Presentation)**
- 122.** **William BM**, Reneau JC, Campbell A, Vilgelm A, Watts M, O'Donnell L, Huang Y, Chung C, Marcos de Lima MJ, Devine S, Vasu S, Dean Lee DA; A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL). Blood 2021; 138 (Supplement 1): 1388. American Society of Hematology Annual Meeting **December 2021**
- 123.** Soror N, Ismail HD, Chung C, **William BM**; Narrowing of the Racial Disparities Gap in Survival of Patients with Mycosis Fungoides: A Longitudinal Analysis of the SEER Database (1988 to 2011). Blood 2021; 138 (Supplement 1): 1392. American Society of Hematology Annual Meeting **December 2021** **(ASH Abstract Achievement Award)**
- 124.** Othman T, Ruel C, Frankel P, Merleev AA, Luxardi G, Maverakis E, Abedi M, Ranganathan R, Zain J, Budde LE, Mei M, Rosenberg AS, Hoeg RT, Costello C, Foss FM, **William BM**, Holland HK, Villalona-Calero M, Sharon E, Tuscano JM; A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses. Blood 2022; 140 (Supplement 1): 9446–9447. American Society of Hematology Annual Meeting **December 2022**
- 125.** Reneau JC, Huang Y, Hanel W, Brammer JE, Chung C, **William BM**; Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas. A4428 American Society of Hematology Annual Meeting **December 2024**
- 126.** **William BM**, Efebera YA: Feasibility of Longitudinal Circulating Tumor DNA (ctDNA) Assessment in Patients with Peripheral and Cutaneous T-Cell Lymphomas. A4441 American Society of Hematology Annual Meeting **December 2024**
- 127.** Tokarski R, Catanzaro J, Mensah R, Scott G, Gillespie C, Caulfield M, Verfurth Q, Ghebremedhin H, Griffin A, Roese A, Scott N, Smiley R, Phillips A, Feinberg D, Lipstraw A, Bope R, Brown M, Burns J, Bangura I, Trikha P, Magzoub G, Green AP, Royero M, James E, **William B**, Efebera Y: Tolerability

of Teclistamab and Talquetamab in Relapse/Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series. ASTCT/CIBMTR Tandem Meetings **February 2025**

128. **William BM**: Feasibility of Longitudinal Circulating Tumor DNA (ctDNA) Assessment in Patients with T-Cell Lymphomas (TCL). International T-cell Lymphoma Forum, La Jolla, CA **March 2025**
129. Le B, Soror N, Ismail HD, **William BM**. Impact of race on survival of patients with primary cutaneous CD30+ T-cell lymphoproliferative disorders: A longitudinal analysis of the SEER database (1988-2011). Society of Investigative Dermatology Annual Meeting **May 2025**
130. Galanina N, Iqbal M, Nousome D, Tin A, Gillespie C, Youngberg H, Sharma S, Ortiz JB, Rodriguez A, Liu M, **William B**. Real-world evaluation of ctDNA for risk stratification across the spectrum of both aggressive and indolent lymphomas. American Society of Hematology Annual Meeting **December 2025** abs25-7763
131. **William B**, Iqbal M, Galanina N, Tomassetti S, Gillespie C, Nousome D, Tin A, Velichko S, Youngberg H, Bridges C, Palsuledesai C, Sharma S, Rodriguez A, Liu M, Narkhede M. Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL). American Society of Hematology Annual Meeting **December 2025** abs25-12057
132. **William BM**: KMT2A-Associated Chromatin and RNA-Turnover Programs Define a Distinct Transcriptional State in Peripheral T-Cell Lymphoma with Potential Menin-KMT2A Dependency. International T-cell Lymphoma Forum, La Jolla, CA **February 2026**
133. Gillespie C, Royero M, Efebera Y, Becker M, **William B**: Unmasking Pancreatic Exocrine Insufficiency in Patients with Gastrointestinal GVHD after Allogeneic Hematopoietic Progenitor Cell Transplantation. ASTCT/CIBMTR Tandem Meetings **February 2026**
134. Gillespie C, Royero M, Efebera Y, Becker M, **William B**: Unmasking Pancreatic Exocrine Insufficiency in Patients with Gastrointestinal GVHD after Allogeneic Hematopoietic Progenitor Cell Transplantation. ASTCT/CIBMTR Tandem Meetings **February 2026**
135. Tokarski R, Catanzaro J, Mensah R, Gillespie C, Scott G, Caulfield M, Verfurth Q, Ghebremedhin H, Griffin A, Roese A, Scott N, Krenelka A, Feinberg D, Martin H, Jacobs Z, Smiley R, Kuhn M, Trikha P, Royero M, James E, Goodridge A, Becker M, **William B**, Efebera Y: Preemptive Tocilizumab with Bispecific Antibodies in Relapsed-Refractory Multiple Myeloma: A Case Series. ASTCT/CIBMTR Tandem Meetings **February 2026**
136. Tokarski R, Catanzaro J, Mensah R, Gillespie C, Scott G, Caulfield M, Verfurth Q, Ghebremedhin H, Griffin A, Roese A, Scott N, Krenelka A, Feinberg D, Martin H, Jacobs Z, Smiley R, Kuhn M, Trikha P, Royero M, James E, Becker M, **William B**, Efebera Y: Teclistamab and Talquetamab in Relapsed-Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series. ASTCT/CIBMTR Tandem Meetings **February 2026**
137. James E, Royero M, Gillespie C, Mensah R, Catanzaro J, Tokarski R, Becker M, Efebera Y, **William B**: A Case Report of Transplantation-Associated Thrombotic Microangiopathy (TA-TMA) in a Patient with Double Heterozygous MCP/CD46 and CFH-H3 Risk Haplotypes. ASTCT/CIBMTR Tandem Meetings **February 2026**
138. **William BM**: Transcriptional programs of apoptotic priming define venetoclax-vulnerable malignant T-cell states in cutaneous T-cell lymphoma ([Oral Presentation](#)). USCLC Annual Meeting and workshop **March 2026**
139. **William BM**: Infusion Product Inflammatory Signatures Predict ICANS but Not Early Response After CD19 CAR-T. International Society of Cell Therapy Annual Meeting (Dublin) **May 2026**

Oral Presentations

National/International Meetings (*designate if invited*)

Date

International

Date	Title	Sponsor
6/14/2023	Advances in Transplant and Cell Therapy for T-Cell Lymphomas	Egyptian Stem Cell Transplantation and Hematological Disease Association (ESHA) 11 th International Meeting (Cairo, Egypt) - <u>Invited</u>
9/28/2022	IEC Therapy for the Treatment of Solid Tumors Webinar: General Concepts and Need for Harmonization of Standards	Foundation for Accreditation of Cellular Therapy (FACT) – <u>Presented this webinar and arranged the Webinar Series as an educational initiative of FACT immune effector cell taskforce</u>
7/1/2021	T-cell Lymphomas: state-of-the-art management and future perspective	Egyptian Stem Cell Transplantation and Hematological Disease Association (ESHA) 9 th International Meeting (Cairo, Egypt) - <u>Invited</u>
3/4/2021	Impact of Opioid Use on Outcomes of Hematopoietic Progenitor Cell Transplantation	American Society of Transplant and Cell Therapy (ASTCT) Survival Interest Group (SIG) annual meeting
10/3/2020	Peripheral T-cell Lymphomas: state-of-the-art management and future perspective	The 7th Annual Ain Shams University International Clinical Oncology Conference (Cairo, Egypt) - <u>Invited</u>
8/20/2020	Cutaneous Lymphomas	Global One Internal Medicine Summer series (Columbus, OH)
12/4/2015	Targeted Therapies & Murine Models in JMML	Juvenile Myelomonocytic Leukemia (JMML) International Working Group (Orlando, FL)

National

Date	Title	Sponsor
4/23/2023	Case Presentation and Debate: Autologous Transplant in T-Cell Lymphoma	23rd Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies - <u>Invited</u>
12/17/2021	Incorporating Novel Agents in the Treatment of T-Cell Lymphoma	Hematology/Oncology Research Seminar – University of Minnesota (Minneapolis, MN)
8/5/2015	Prevention of relapse after hematopoietic stem cell transplant	Hematological malignancies research seminar – University of Nebraska Medical Center (Omaha, NE)
6/23/2015	Prevention of Relapse after Hematopoietic Stem Cell Transplantation	Hematology/Oncology Research Seminar – Oregon Health & Science University Knight Cancer Institute (Portland, OR)
6/23/2015	Prevention of Relapse after Hematopoietic Stem Cell Transplantation	Hematology/Oncology Research Seminar – Oregon Health & Science University Knight Cancer Institute (Portland, OR)
5/21/2015	Oral Azacitidine Maintenance After Allogeneic Stem Cell Transplantation	Hematology/Oncology Research Seminar – Ochsner Clinic (New Orleans, LA)
5/14/2015	Prevention of Relapse after Hematopoietic Stem Cell	Hematology/Oncology Research Seminar- University of North Carolina School of Medicine (Chapel Hill, NC)

	Transplantation	
5/11/2015	Oral Azacitidine Maintenance After Allogeneic Stem Cell Transplantation	Hematology/Oncology Research Seminar- Wake Forest University School of Medicine (Winston-Salem, NC)
4/6/2015	Oral Azacitidine Maintenance After Allogeneic Stem Cell Transplantation	Hematology/Oncology Research Seminar- Virginia Commonwealth University School of Medicine (Richmond, VA)

Local/Regional Meetings

Date	Title	Sponsor
10/10/2026	The Next Era of Curative Therapy in DLBCL; from Combination Trials to MRD-Informed Outcomes	OhioHealth Annual Cancer Conference (Columbus, OH)
4/23/2026	Building a Clinically Integrated Biorepository and Functional Cell Testing Platform	OhioHealth 3 rd Annual Blood and Marrow Transplant Quality and Research Symposium (virtual)
3/16/2026	Neurological toxicities of Immune Effector Cell Therapies	OhioHealth Neurology Education Conference (virtual)
3/8/2024	Bispecific Antibodies	Permanente Medicine 2024 National Excellence in Cancer Care Symposium (San Francisco, CA) Invited – Keynote Speaker
2/15/2024	AMS Physician Panel	OSU Arab Medical Society (Columbus, OH)
10/12/2023	Lymphoma management and CAR-T Cell Therapy - A state of the art update	OhioHealth Virtual Cancer Conference (Columbus, OH)
1/20/2017	ASH Review: Blood and Marrow Transplantation	OSU American Society of Hematology (ASH) 2017 Review (Columbus, OH)
10/28/2016	Non-Hodgkin Lymphoma	OSU Hematology Preceptorship for Sanofi-Genzyme (Columbus, OH)
1/22/2016	ASH Review: Blood and Marrow Transplantation	OSU American Society of Hematology (ASH) 2016 Review (Columbus, OH)

Grand Rounds Presentations

Date	Title	Sponsor
9/4/2018	Blood and Marrow Transplantation Yesterday, Today, and Tomorrow	Wyandot Memorial Hospital Grand Rounds, Upper Sandusky, OH (James Outreach)
6/30/2017	Update on Lymphomas	Blanchard Valley Regional Health Center (Findlay, OH) Grand Rounds (James Outreach)
3/25/2015	Hematology Cases for Primary Care Physician	Summa Western Reserve Hospital (Cuyahoga Falls, OH) Grand Rounds
3/20/2015	Hematology Cases for Primary Care Physician	Southwest General Health Center (Middleburg Heights, OH) Grand Rounds

Social Media/Patient Education Programs

MediMex Interview

ASH 2024: Highlights in aggressive lymphomas
<https://medimix.be/hematology/ash-sandiego-2024-highlight-7/>

VuMedi Online Education Platform

IL-21 Expanded NK Cells + Mogamulizumab for Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas
<https://www.vumedi.com/video/il-21-expanded-nk-cells-mogamulizumab-for-cutaneous-t-cell-lymphomas-or-adult-t-cell-leukemialymphom/>

Cutaneous Lymphoma 101: Overview on Diagnosis, Staging and Prognosis
<https://www.vumedi.com/video/cutaneous-lymphoma-101-overview-on-diagnosis-staging-and-prognosis/>
(7/2024)

Preliminary Results of Phase II Trial of Brentuximab Vedotin and Lenalidomide in Relapsed / Refractory Cutaneous / Peripheral T-Cell Lymphomas
<https://www.vumedi.com/video/a-phase-ii-trial-of-brentuximab-vedotin-bv-and-lenalidomide-len-in-relapsed-and-refractory-rr-cutane/>
(10/2019)

BMT Infonet – CAR T-cell Therapy for Lymphoma: What's Involved, Potential Outcomes- 2024 Virtual Patient Survivorship Symposium
<https://youtu.be/bLptNAjnyKo>
(5/2024)

Cutaneous Lymphoma Foundation – Cutaneous Lymphoma 101 - 2022 Virtual Patient Conference
<https://youtu.be/bLptNAjnyKo>
(7/2022)

Recognized as an **Expertscape** Expert in T-Cell Lymphoma
<https://twitter.com/expertscapenews/status/1468626525486473219>
(12/2021)

Cutaneous Lymphoma Foundation – Answers from the Experts - Q&A with Expert Clinicians
<https://www.youtube.com/watch?v=FZZKzxZ80zc&t=250s>
(11/2021)

Cutaneous Lymphoma Foundation – Live Chat on Clinical Trials for Cutaneous Lymphoma
<https://www.youtube.com/watch?v=K99-pocUh9I&t=151s>
(9/2019)

OncLive TV - Brentuximab Vedotin/Lenalidomide in Cutaneous/Peripheral T-Cell Lymphomas
<https://www.youtube.com/watch?v=DcvkQkKpCPU>
(9/2019)

MDedge - Combo treatment may improve quality of life in CTCL
<https://www.mdedge.com/hematology-oncology/article/193256/t-cell-lymphomas/combo-treatment-may-improve-quality-life-ctcl>
(1/2019)

Other Media References

[List CDs, interviews, simulations, films, websites, webinars, case vignettes you authored and are in use, and any other creative work products. Indicate your role in the creation of the product – creator, author, co-author, webmaster, etc.]

Date

- Provided expert point of view to ASCO Post 2020
<https://ascopost.com/issues/february-10-2020/epov-basem-william/>
<https://ascopost.com/issues/february-25-2020-supplement-conference-highlights-ash-2019/epov-basem-william-and-caron-jacobson/>
<https://ascopost.com/issues/february-25-2020/epov-basem-william/>
- Quoted in Cutaneous Lymphoma Foundation Article 2021
<https://www.clfoundation.org/cutaneous-lymphoma-and-fatigue>
- E-Book/Special Issue Article Collection on Cutaneous Lymphoma (Editor) 2021
 -Published in *Frontiers in Oncology*
<https://www.frontiersin.org/research-topics/8509/cutaneous-t-cell-lymphomas>
- Health News Press release 2023
https://pressrelease.healthcare/basem-m-william-md-mrcpuk-facp-a-lymphoma-cell-therapy-specialist-with-ohiohealth-arthur-g-h-bing-md-cancer-center-and-riverside-methodist-hospital.html?utm_medium=email&_hsmt=214467092&_hsenc=p2ANqtz-86AerDLOfYqAVzmZfDBwsbpFJoovJUNpeIUuEglhVpDP0HV1seKPs-gaybVNG9wuQIFZ5FuIrrq4AnsKvKicNgnYZBsQ&utm_content=214467092&utm_source=hs_automation
- Cityscene Interview 2023
<https://www.cityscenecolumbus.com/health/how-to-boost-your-immune-system-in-a-busy-world/>
- OhioHealth Cancer Patient Gets Married at OhioHealth Riverside Methodist Hospital 2023
 OhioHealth Newsroom and multiple media agencies
<https://newsroom.ohiohealth.com/ohiohealth-cancer-patient-gets-married-at-ohiohealth-riverside-methodist-hospital/>
<https://wpde.com/news/offbeat/ohiohealth-cancer-patient-married-riverside-methodist-hospital-second-round-of-chemo>
<https://www.10tv.com/article/news/local/couple-gets-married-at-ohiohealth-riverside-methodist/530-6fd1c05b-f033-4f53-8102-b6a1d26b635c>
<https://cwomaha.tv/news/offbeat/ohiohealth-cancer-patient-married-riverside-methodist-hospital-second-round-of-chemo>
<https://original.newsbreak.com/@news-wave-1771723/3219570553161-ohiohealth-cancer-patient-finds-love-and-marriage-at-riverside-methodist-hospital>
<https://foxillinois.com/news/offbeat/ohiohealth-cancer-patient-married-riverside-methodist-hospital-second-round-of-chemo>
- Patient Power: AML Leukemia Survival Rate by Age: Key Insights & Statistics 2023
<https://www.patientpower.info/acute-myeloid-leukemia/aml-leukemia-survival-rate-by-age>
- OhioHealth – Medical Minute 2024
- OhioHealth Blood and Marrow Transplant and Cellular Therapy Program
<https://newsroom.ohiohealth.com/medical-minute-ohiohealth-blood-and-marrow-transplant-and-cellular-therapy-program/>
- Bone Marrow Harvesting
<https://newsroom.ohiohealth.com/medical-minute-bone-marrow-harvesting/>
- 10TV: Columbus community supports 8-year-old girl in urgent need of bone marrow donor 2025
<https://www.10tv.com/article/news/local/columbus-community-bone-marrow-match-8-year-old-girl-kaia-julka/530-009a7991-30de-4665-b1f8-8706247d5c24>

Grant Reviewer/Study Sections

American Society of Hematology (ASH) Research Training Awards for Fellows	2026
American Society of Hematology (ASH) Basic/Translational Junior Faculty Scholar Awards	2025
American Society of Hematology (ASH) Research Training Awards for Fellows	2025
American Society of Hematology (ASH) awards Medical Students Honors Study Section	2024
Ad Hoc Grant Reviewer/International Expert, Belgian Foundation against Cancer	2018
Ad Hoc Grant Reviewer/International Expert, Cancer Research UK	2018